

=> b hcplus

FILE 'HCAPLUS' ENTERED AT 10:21:38 ON 21 MAY 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 May 2003 VOL 138 ISS 21  
 FILE LAST UPDATED: 20 May 2003 (20030520/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 136

L11	1	SEA FILE=REGISTRY ABB=ON	PLU=ON	"TETRAM'RISTOYL CARDIOLIPIN"/CN
L15	8	SEA FILE=REGISTRY ABB=ON	PLU=ON	"1-PALMITOYL"(S) "LECITHIN"
L16	8	SEA FILE=REGISTRY ABB=ON	PLU=ON	"1-PALMITOYL"(P) "LECITHIN"
L17	8	SEA FILE=REGISTRY ABB=ON	PLU=ON	"1-PALMITOYL"(L) "LECITHIN"
L18	8	SEA FILE=REGISTRY ABB=ON	PLU=ON	L15 OR L16 OR L17
L19	2	SEA FILE=REGISTRY ABB=ON	PLU=ON	L18 AND "OLEOYL"
L20	2	SEA FILE=REGISTRY ABB=ON	PLU=ON	L19 AND "GLYCERO"
L21	1	SEA FILE=REGISTRY ABB=ON	PLU=ON	L20 AND "SN"
L24	5366	SEA FILE=HCAPLUS ABB=ON	PLU=ON	CARDIOLIPINS/CT
L25	17997	SEA FILE=HCAPLUS ABB=ON	PLU=ON	LECITHINS/CT
L33	125092	SEA FILE=HCAPLUS ABB=ON	PLU=ON	ANTIGENS/CT
L36	13	SEA FILE=HCAPLUS ABB=ON	PLU=ON	(L24 OR L11) AND (L25 OR L21) AND L33

=> d que 138

L11	1	SEA FILE=REGISTRY ABB=ON	PLU=ON	"TETRAMYRISTOYL CARDIOLIPIN"/CN
L15	8	SEA FILE=REGISTRY ABB=ON	PLU=ON	"1-PALMITOYL"(S) "LECITHIN"
L16	8	SEA FILE=REGISTRY ABB=ON	PLU=ON	"1-PALMITOYL"(P) "LECITHIN"
L17	8	SEA FILE=REGISTRY ABB=ON	PLU=ON	"1-PALMITOYL"(L) "LECITHIN"
L18	8	SEA FILE=REGISTRY ABB=ON	PLU=ON	L15 OR L16 OR L17
L19	2	SEA FILE=REGISTRY ABB=ON	PLU=ON	L18 AND "OLEOYL"
L20	2	SEA FILE=REGISTRY ABB=ON	PLU=ON	L19 AND "GLYCERO"
L21	1	SEA FILE=REGISTRY ABB=ON	PLU=ON	L20 AND "SN"
L22	1	SEA FILE=REGISTRY ABB=ON	PLU=ON	ETHANOL/CN
L23	1	SEA FILE=REGISTRY ABB=ON	PLU=ON	CHOLESTEROL/CN
L24	5366	SEA FILE=HCAPLUS ABB=ON	PLU=ON	CARDIOLIPINS/CT
L25	17997	SEA FILE=HCAPLUS ABB=ON	PLU=ON	LECITHINS/CT
L26	114986	SEA FILE=HCAPLUS ABB=ON	PLU=ON	ALCOHOLS/CT

L35 704 SEA FILE=HCAPLUS ABB=ON PLU=ON (L24 OR L11) AND (L25 OR L21)

L37 95435 SEA FILE=HCAPLUS ABB=ON PLU=ON CHOLESTEROL+NT/CT

L38 11 SEA FILE=HCAPLUS ABB=ON PLU=ON L35 AND (L23 OR L37) AND (L26 OR L22)

=> d que 139

L11 1 SEA FILE=REGISTRY ABB=ON PLU=ON "TETRAMYRISTOYL CARDIOLIPIN"/CN

L15 8 SEA FILE=REGISTRY ABB=ON PLU=ON "1-PALMITOYL" (S) "LECITHIN"

L16 8 SEA FILE=REGISTRY ABB=ON PLU=ON "1-PALMITOYL" (P) "LECITHIN"

L17 8 SEA FILE=REGISTRY ABB=ON PLU=ON "1-PALMITOYL" (L) "LECITHIN"

L18 8 SEA FILE=REGISTRY ABB=ON PLU=ON L15 OR L16 OR L17

L19 2 SEA FILE=REGISTRY ABB=ON PLU=ON L18 AND "OLEOYL"

L20 2 SEA FILE=REGISTRY ABB=ON PLU=ON L19 AND "GLYCERO"

L21 1 SEA FILE=REGISTRY ABB=ON PLU=ON L20 AND "SN"

L24 5366 SEA FILE=HCAPLUS ABB=ON PLU=ON CARDIOLIPINS/CT

L25 17997 SEA FILE=HCAPLUS ABB=ON PLU=ON LECITHINS/CT

L27 42188 SEA FILE=HCAPLUS ABB=ON PLU=ON DIAGNOSIS/CT

L28 801 SEA FILE=HCAPLUS ABB=ON PLU=ON SYPHILIS/CT

L29 862 SEA FILE=HCAPLUS ABB=ON PLU=ON TREPONEMA PALLIDUM+NT/CT

L30 5200 SEA FILE=HCAPLUS ABB=ON PLU=ON FLOCCULATION/CT

L31 1397 SEA FILE=HCAPLUS ABB=ON PLU=ON AGGLUTINATION/CT

L32 42063 SEA FILE=HCAPLUS ABB=ON PLU=ON IMMUNOASSAY+NT/CT

L35 704 SEA FILE=HCAPLUS ABB=ON PLU=ON (L24 OR L11) AND (L25 OR L21)

L39 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L35 AND (L27 OR L32 OR L30 OR L31) AND (L29 OR L28)

=> s 136 or 138 or 139

L89 23 L36 OR L38 OR L39

=> b medline

FILE 'MEDLINE' ENTERED AT 10:22:05 ON 21 MAY 2003

FILE LAST UPDATED: 20 MAY 2003 (20030520/UP). FILE COVERS 1958 TO DATE.

On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/changes2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 152

L40 48405 SEA FILE=MEDLINE ABB=ON PLU=ON ANTIGENS/CT

L41 2446 SEA FILE=MEDLINE ABB=ON PLU=ON CARDIOLIPINS/CT

L42 23663 SEA FILE=MEDLINE ABB=ON PLU=ON PHOSPHATIDYLCHOLINES+NT/CT

L51 461 SEA FILE=MEDLINE ABB=ON PLU=ON L41 AND L42

L52 4 SEA FILE=MEDLINE ABB=ON PLU=ON L51 AND L40

=> d que 156

L40	48405	SEA FILE=MEDLINE ABB=ON	PLU=ON	ANTIGENS/CT
L41	2446	SEA FILE=MEDLINE ABB=ON	PLU=ON	CARDIOLIPINS/CT
L42	23663	SEA FILE=MEDLINE ABB=ON	PLU=ON	PHOSPHATIDYLCHOLINES+NT/CT
L43	397511	SEA FILE=MEDLINE ABB=ON	PLU=ON	ALCOHOLS+NT/CT
L44	45906	SEA FILE=MEDLINE ABB=ON	PLU=ON	ETHANOL/CT
L45	3717330	SEA FILE=MEDLINE ABB=ON	PLU=ON	DIAGNOSIS+NT/CT
L46	245869	SEA FILE=MEDLINE ABB=ON	PLU=ON	IMMUNOASSAY+NT/CT
L47	31540	SEA FILE=MEDLINE ABB=ON	PLU=ON	AGGLUTINATION TESTS+NT/CT
L48	244	SEA FILE=MEDLINE ABB=ON	PLU=ON	FLOCCULATION TESTS/CT
L49	10913	SEA FILE=MEDLINE ABB=ON	PLU=ON	SYPHILIS+NT/CT
L50	2047	SEA FILE=MEDLINE ABB=ON	PLU=ON	TREPONEMA PALLIDUM/CT
L51	461	SEA FILE=MEDLINE ABB=ON	PLU=ON	L41 AND L42
L53	70383	SEA FILE=MEDLINE ABB=ON	PLU=ON	CHOLESTEROL/CT
L56	0	SEA FILE=MEDLINE ABB=ON	PLU=ON	L51 AND (L43 OR L44) AND L53 AND (L40 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50)

=> d que 159

L41	2446	SEA FILE=MEDLINE ABB=ON	PLU=ON	CARDIOLIPINS/CT
L42	23663	SEA FILE=MEDLINE ABB=ON	PLU=ON	PHOSPHATIDYLCHOLINES+NT/CT
L45	3717330	SEA FILE=MEDLINE ABB=ON	PLU=ON	DIAGNOSIS+NT/CT
L46	245869	SEA FILE=MEDLINE ABB=ON	PLU=ON	IMMUNOASSAY+NT/CT
L47	31540	SEA FILE=MEDLINE ABB=ON	PLU=ON	AGGLUTINATION TESTS+NT/CT
L48	244	SEA FILE=MEDLINE ABB=ON	PLU=ON	FLOCCULATION TESTS/CT
L49	10913	SEA FILE=MEDLINE ABB=ON	PLU=ON	SYPHILIS+NT/CT
L50	2047	SEA FILE=MEDLINE ABB=ON	PLU=ON	TREPONEMA PALLIDUM/CT
L51	461	SEA FILE=MEDLINE ABB=ON	PLU=ON	L41 AND L42
L59	11	SEA FILE=MEDLINE ABB=ON	PLU=ON	L51 AND L45 AND (L46 OR L47 OR L48) AND (L49 OR L50)

=> d que 165

L41	2446	SEA FILE=MEDLINE ABB=ON	PLU=ON	CARDIOLIPINS/CT
L42	23663	SEA FILE=MEDLINE ABB=ON	PLU=ON	PHOSPHATIDYLCHOLINES+NT/CT
L46	245869	SEA FILE=MEDLINE ABB=ON	PLU=ON	IMMUNOASSAY+NT/CT
L47	31540	SEA FILE=MEDLINE ABB=ON	PLU=ON	AGGLUTINATION TESTS+NT/CT
L48	244	SEA FILE=MEDLINE ABB=ON	PLU=ON	FLOCCULATION TESTS/CT
L49	10913	SEA FILE=MEDLINE ABB=ON	PLU=ON	SYPHILIS+NT/CT
L50	2047	SEA FILE=MEDLINE ABB=ON	PLU=ON	TREPONEMA PALLIDUM/CT
L51	461	SEA FILE=MEDLINE ABB=ON	PLU=ON	L41 AND L42
L61	19	SEA FILE=MEDLINE ABB=ON	PLU=ON	L51 AND (L49 OR L50) (L) (DI OR DIAGNOSIS)
L65	6	SEA FILE=MEDLINE ABB=ON	PLU=ON	L61 AND ((L46 OR L47 OR L48) OR ASSAY? OR DETECT? (3A) SYPHILIS)

=> s 152 or 159 or 165

L90            18 L52 OR L59 OR L65

=> b embase

FILE 'EMBASE' ENTERED AT 10:22:41 ON 21 MAY 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE COVERS 1974 TO 19 May 2003 (20030519/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 179

L67	23748 SEA FILE=EMBASE ABB=ON	PLU=ON	ANTIGEN/CT
L68	1740 SEA FILE=EMBASE ABB=ON	PLU=ON	CARDIOLIPIN/CT
L69	14581 SEA FILE=EMBASE ABB=ON	PLU=ON	PHOSPHATIDYLCHOLINE/CT
L78	387 SEA FILE=EMBASE ABB=ON	PLU=ON	L68 AND L69
L79	3 SEA FILE=EMBASE ABB=ON	PLU=ON	L78 AND L67

=> d que 180

L68	1740 SEA FILE=EMBASE ABB=ON	PLU=ON	CARDIOLIPIN/CT
L69	14581 SEA FILE=EMBASE ABB=ON	PLU=ON	PHOSPHATIDYLCHOLINE/CT
L70	76569 SEA FILE=EMBASE ABB=ON	PLU=ON	ALCOHOL/CT
L71	50722 SEA FILE=EMBASE ABB=ON	PLU=ON	CHOLESTEROL/CT
L78	387 SEA FILE=EMBASE ABB=ON	PLU=ON	L68 AND L69
L80	1 SEA FILE=EMBASE ABB=ON	PLU=ON	L78 AND L70 AND L71

=> d que 181

L68	1740 SEA FILE=EMBASE ABB=ON	PLU=ON	CARDIOLIPIN/CT
L69	14581 SEA FILE=EMBASE ABB=ON	PLU=ON	PHOSPHATIDYLCHOLINE/CT
L72	1598848 SEA FILE=EMBASE ABB=ON	PLU=ON	DIAGNOSIS/CT
L73	130154 SEA FILE=EMBASE ABB=ON	PLU=ON	IMMUNOASSAY+NT/CT
L74	1748 SEA FILE=EMBASE ABB=ON	PLU=ON	AGGLUTINATION TEST/CT
L75	2020 SEA FILE=EMBASE ABB=ON	PLU=ON	FLOCCULATION/CT
L76	6703 SEA FILE=EMBASE ABB=ON	PLU=ON	SYPHILIS/CT
L77	1952 SEA FILE=EMBASE ABB=ON	PLU=ON	TREPONEMA PALLIDUM/CT
L78	387 SEA FILE=EMBASE ABB=ON	PLU=ON	L68 AND L69
L81	4 SEA FILE=EMBASE ABB=ON	PLU=ON	L78 AND (L72 OR L73 OR L74 OR L75) AND (L76 OR L77)

=> d que 182

L68	1740 SEA FILE=EMBASE ABB=ON	PLU=ON	CARDIOLIPIN/CT
L69	14581 SEA FILE=EMBASE ABB=ON	PLU=ON	PHOSPHATIDYLCHOLINE/CT
L76	6703 SEA FILE=EMBASE ABB=ON	PLU=ON	SYPHILIS/CT
L77	1952 SEA FILE=EMBASE ABB=ON	PLU=ON	TREPONEMA PALLIDUM/CT
L78	387 SEA FILE=EMBASE ABB=ON	PLU=ON	L68 AND L69
L82	2 SEA FILE=EMBASE ABB=ON	PLU=ON	L78 AND (L76 OR L77) (L) (DI OR DIAGNOSIS)

=> s 179 or 180 or 181 or 182

L91 7 L79 OR L80 OR L81 OR L82

=> b wpix drugu

FILE 'WPIX' ENTERED AT 10:23:20 ON 21 MAY 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGU' ENTERED AT 10:23:20 ON 21 MAY 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

=> d que 186

L84	248 SEA CARDIOLIPIN AND (LECITHIN OR PHOSPHATIDYLCHOLINE)		
L86	3 SEA L84 AND (ALCOHOL OR ETHANOL) AND CHOLESTEROL AND (DIAGNOSIS)		

OR IMMUNOASSAY OR ASSAY? OR AGGLUTINAT? OR FLOCCULAT? OR  
SYPHILIS OR TREPONEMA?)

=> d que 187

L84 248 SEA CARDIOLIPIN AND (LECITHIN OR PHOSPHATIDYLCHOLINE)  
L87 5 SEA L84 AND (DIAGNOSIS OR IMMUNOASSAY OR ASSAY? OR AGGLUTINAT?  
OR FLOCCULAT?) AND (SYPHILIS OR TREPONEMA?)

=> s 186 or 187

L92 6 L86 OR L87

=> dup rem 190 189 191 192

FILE 'MEDLINE' ENTERED AT 10:23:57 ON 21 MAY 2003

FILE 'HCAPLUS' ENTERED AT 10:23:57 ON 21 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:23:57 ON 21 MAY 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'WPIX' ENTERED AT 10:23:57 ON 21 MAY 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGU' ENTERED AT 10:23:57 ON 21 MAY 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

PROCESSING COMPLETED FOR L90

PROCESSING COMPLETED FOR L89

PROCESSING COMPLETED FOR L91

PROCESSING COMPLETED FOR L92

L93 49 DUP REM L90 L89 L91 L92 (5 DUPLICATES REMOVED)

=> d ibib ab hitind 193 1-49

L93 ANSWER 1 OF 49 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:314746 HCAPLUS

DOCUMENT NUMBER: 136:330564

TITLE: Lipid-protein-sugar microparticles for drug delivery

INVENTOR(S): Kohane, Daniel S.; Lipp, Michael M.; Langer, Robert S.

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032398	A2	20020425	WO 2001-US32378	20011016
WO 2002032398	A3	20030109		

W: CA, JP

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE, TR

US 2002150621 A1 20021017 US 2001-981020 20011016  
 PRIORITY APPLN. INFO.: US 2000-240636P P 20001016

AB Lipid-protein-sugar microparticles (LPSPs) are provided as a vehicle for drug delivery. Any therapeutic, diagnostic, or prophylactic agent may be encapsulated in a lipid-protein-sugar matrix to form microparticles. Preferably the diam. of the LPSP ranges from 50 to 10 .mu.m. The particles may be prep'd. by using any known lipid (e.g., DPPC), protein (e.g., albumin), or sugar (e.g., lactose). Methods of prep'g. and administering the particles are also provided. Methods of providing a nerve block are also provided by administering LPSPs with a local anesthetic (e.g., bupivacaine) within the vicinity of a nerve. Title microparticles (DPPC-albumin-lactose) were prep'd. contg. bupivacaine. The drug release from the particles was complete within 24 h.

IC ICM A61K009-00  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1  
 IT **Alcohols, biological studies**  
 Amides, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (fatty; lipid-protein-sugar microparticles for drug delivery)  
 IT Albumins, biological studies  
 Antibodies  
**Antigens**  
 Carbohydrates, biological studies  
**Cardiolipins**  
 Cerebrosides  
 Enzymes, biological studies  
 Fatty acids, biological studies  
 Glycerides, biological studies  
 Glycerophospholipids  
 Glycosaminoglycans, biological studies  
**Lecithins**  
 Lipids, biological studies  
 Lysophosphatidylcholines  
 Phosphatidic acids  
 Phosphatidylcholines, biological studies  
 Phosphatidylethanolamines, biological studies  
 Phosphatidylinositols  
 Phosphatidylserines  
 Phospholipids, biological studies  
 Polymers, biological studies  
 Polyoxyalkylenes, biological studies  
 Proteins  
 Sialic acids  
 Sphingomyelins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (lipid-protein-sugar microparticles for drug delivery)  
 IT 50-99-7, Glucose, biological studies 57-10-3, Palmitic acid, biological studies 57-48-7, Fructose, biological studies **57-88-5**,  
 Cholesterol, biological studies **57-88-5D**, Cholesterol, esters  
 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 59-46-1, Procaine 63-42-3, Lactose 69-65-8, Mannitol  
 69-79-4, Maltose 85-79-0, Dibucaine 94-24-6, Tetracaine 96-88-8,  
 Mepivacaine 110-27-0, Isopropyl myristate 112-80-1, Oleic acid,  
 biological studies 124-22-1, Dodecylamine 124-30-1, Stearylamine  
 137-58-6, Lidocaine 143-27-1, Hexadecylamine 512-69-6, Raffinose  
 1190-63-2, Hexadecyl stearate 1323-38-2, Glyceryl ricinoleate

2197-63-9, Dicetyl phosphate 2462-63-7, DOPE 2644-64-6, DPPC  
 2763-96-4, Muscimol 4537-77-3, DPPG 9001-37-0, Glucose oxidase  
 9002-89-5, Poly(vinyl alcohol) 9002-92-0, Polyethylene glycol lauryl  
 ether 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethyl  
 cellulose 9004-34-6, Cellulose, biological studies 9004-53-9, Dextrin  
 9004-54-0, Dextran, biological studies 9004-54-0D, Dextran, derivs.  
 9004-61-9, Hyaluronic acid 9004-67-5, Methyl Cellulose 9005-25-8,  
 Starch, biological studies 9007-28-7, Chondroitin sulfate 9012-76-4,  
 Chitosan 18010-40-7, Bupivacaine hydrochloride 21829-25-4, Nifedipine  
 23964-58-1, Articaine 24730-31-2, Surfactin 25301-02-4, Tyloxapol  
 25322-68-3, Polyethylene glycol 25322-68-3D, Polyethylene glycol,  
 phosphatidylethanolamine conjugates 26266-58-0, Span 85 36653-82-4,  
 Hexadecanol 64044-51-5, Lactose monohydrate 68737-67-7, DOPC  
 104162-48-3, DOTMA 106392-12-5, Poloxamer  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (lipid-protein-sugar microparticles for drug delivery)

L93 ANSWER 2 OF 49 HCPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:314744 HCPLUS  
 DOCUMENT NUMBER: 136:330527  
 TITLE: Lipid-protein-sugar particles for delivery of nucleic acids  
 INVENTOR(S): Kohane, Daniel S.; Anderson, Daniel G.; Langer, Robert S.  
 PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA  
 SOURCE: PCT Int. Appl., 82 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032396	A2	20020425	WO 2001-US32210	20011016
WO 2002032396	A3	20030206		

W: CA, JP

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, TR

US 2002150626 A1 20021017 US 2001-981460 20011016

PRIORITY APPLN. INFO.: US 2000-240698P P 20001016

AB Lipid-protein-sugar particles (LPSPs) are provided as a vehicle for the delivery of nucleic acids. Any polynucleotide (e.g., DNA, RNA) may be encapsulated in a lipid-protein-sugar matrix to form microparticles. Preferably the diam. of the LPSP ranges from 50 nm to 10 .mu.m. The particles may be prep'd. using any known lipid (e.g., DPPC), protein (e.g., albumin), or sugar (e.g., lactose). Methods of prep'g. the particles and administering the particles for gene therapy are also provided. Preferably the methods of prep'g. the LPSPs do not significantly damage the polynucleotide to be delivered.

IC ICM A61K009-00

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 15

IT **Antigens**

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(bacterial; lipid-protein-sugar particles for delivery of nucleic acids)

IT **Alcohols, biological studies**

Amides, biological studies

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(fatty; lipid-protein-sugar particles for delivery of nucleic acids)

IT **Albumins, biological studies**

Antibodies

Carbohydrates, biological studies

**Cardiolipins**

**Cardiolipins**

Cerebrosides

DNA

Diglycerides

Enzymes, biological studies

Fatty acids, biological studies

Glycosaminoglycans, biological studies

**Lecithins**

Lipids, biological studies

Lysophosphatidylcholines

Phosphatidic acids

Phosphatidylcholines, biological studies

Phosphatidylethanolamines, biological studies

Phosphatidylinositols

Phosphatidylserines

Phospholipids, biological studies

Polymers, biological studies

Polynucleotides

Polyoxyalkylenes, biological studies

Proteins

RNA

Sialic acids

Sphingomyelins

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(lipid-protein-sugar particles for delivery of nucleic acids)

IT 57-10-3, Palmitic acid, biological studies 57-48-7, Fructose, biological

studies 57-88-5, Cholesterol, biological studies

57-88-5D, Cholesterol, esters 58-86-6, Xylose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 69-79-4, Maltose 110-15-6D, Succinic acid, glycerides 110-27-0, Isopropyl myristate 112-80-1, Oleic acid, biological studies 124-22-1, Dodecylamine 124-30-1, Stearylamine 143-27-1, Hexadecylamine 475-31-0 512-69-6, Raffinose 629-70-9, Palmityl Acetate 1190-63-2, Hexadecyl stearate 2197-63-9, Dicetylphosphate 2462-63-7, Dope 2644-64-6, Dipalmitoylphosphatidylcholine 4537-77-3, Dipalmitoylphosphatidylglycerol 1 9000-11-7, Carboxymethyl cellulose 9001-37-0, Glucose oxidase 9002-92-0 9004-34-6, Cellulose, biological studies 9004-53-9, Dextrin 9004-54-0, Dextran, biological studies 9004-61-9, Hyaluronic acid 9004-67-5, Methyl cellulose 9005-25-8, Starch, biological studies 9007-28-7, Chondroitin sulfate 9012-76-4, Chitosan 24730-31-2, Surfactin 25301-02-4, Tyloxapol 25322-68-3, Polyethylene glycol 26266-58-0, Span 85 51260-59-4, Hexadecanol 58561-47-0 68737-67-7, Dioleoylphosphatidylcholine 104162-48-3, Dotma

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (lipid-protein-sugar particles for delivery of nucleic acids)

L93 ANSWER 3 OF 49 HCAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:928122 HCAPLUS  
 DOCUMENT NUMBER: 138:12504  
 TITLE: Method for assaying biomolecules and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques  
 INVENTOR(S): Smith, Jack V.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 46 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002182600	A1	20021205	US 2001-829563	20010411
PRIORITY APPLN. INFO.:			US 2001-829563	20010411

AB The present invention is a method for the use of particles made up of nucleotides or fragments of base groups of DNA and RNA mols. herein referred to as synthetic nucleounits which can be used as recognition mols. with specificity and sensitivity significantly greater than that of antibodies which are used in clin. diagnostics, biotechnol., and research. The method for detecting an analyte using nucleounits targeted to the analyte comprises (1) identifying a nucleounit from a mixt. of synthetic random sequences of nucleounit libraries, (2) conjugating the nucleounit to an indicator for the analyte, and (3) detecting the analyte using the nucleounit-indicator conjugate in a buffer. Step 1 is carried out by (a) contacting the analyte with the mixt. of synthetic random sequences of nucleounit libraries such that some nucleounits bind the analyte, (b) removing the unbound nucleounits by partitioning, and (c) amplifying the remaining nucleounits by PCR to obtain an enriched soln. of nucleounits with high affinity for the analyte. Thus, a method and lateral flow test strip for detection of cytomegalovirus (CMV) presence in a biol. sample such as serum or urine is described. The strip is prep'd. with three solns., one contg. anti-CMV antibodies, one contg. "nucleounit to CMV antibody conjugated to red microparticles" and "red microparticles", and another contg. "nucleounit to colored particles". The "nucleounit" may be an oligonucleotide aptamer specific for anti-CMV antibodies.

IC ICM C12Q001-68

NCL 435006000

CC 9-16 (Biochemical Methods)

IT **Antigens**

RL: ANT (Analyte); ANST (Analytical study)  
 (EBNA (Epstein-Barr virus-assocd. nuclear antigen), IgG binding to; method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT **Antigens**

RL: ANT (Analyte); ANST (Analytical study)

(Epstein-Barr early; method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT **Antigens**

RL: ANT (Analyte); ANST (Analytical study)  
(VCA (viral capsid antigen), IgG and IgM binding to Epstein-Barr; method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT **Cardiolipins**

RL: ANT (Analyte); ANST (Analytical study)  
(antibodies binding to; method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT **Antigens**

RL: ANT (Analyte); ANST (Analytical study)  
(cancer antigen 125; method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT **Antigens**

RL: ANT (Analyte); ANST (Analytical study)  
(extractable nuclear; method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT **Albumins, analysis**

**Alcohols, analysis**

Antibodies

Apolipoproteins

Bile acids

Cannabinoids

Carotenes, analysis

Catecholamines, analysis

Estrogens

Fatty acids, analysis

Ferritins

Fibrinogens

Gastric acid

Glycerides, analysis

Gonadotropins

Haptoglobin

Hemoglobins

Hemoglobins, methemoglobins

Hemopexins

Immunoglobulins

Ketone bodies

**Lecithins**

Lipoproteins

Melanins

Mucopolysaccharides, analysis

Myelin basic protein

Myoglobins

Opioids

Pentoses

Phenols, analysis

Phospholipids, analysis

Prostaglandins

Prostate-specific antigen

Rheumatoid factors

Thyroglobulin

Transcortins

Transferrins

Transthyretin

Vitamins

.alpha.1-Acid glycoprotein

RL: ANT (Analyte); ANST (Analytical study)

(method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liq., and dry chem. techniques)

IT 50-00-0, Formaldehyde, analysis 50-02-2, Dexamethasone 50-06-6, Phenobarbital, analysis 50-22-6, Corticosterone 50-23-7, Cortisol 50-27-1, Estriol 50-28-2, Estradiol, analysis 50-33-9, Phenylbutazone, analysis 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, analysis 50-56-6, Oxytocin, analysis 50-67-9, Serotonin, analysis 50-81-7, Ascorbic acid, analysis 50-99-7, Glucose, analysis 51-06-9, Procainamide 51-35-4, Hydroxyproline 51-48-9, Thyroxine, analysis 52-39-1, Aldosterone 52-90-4, Cysteine, analysis 53-02-1, Tetrahydrocortisol 53-16-7, Estrone, analysis 53-43-0, Dehydroepiandrosterone 54-16-0, 5-Hydroxyindoleacetic acid, analysis 54-36-4, Metyrapone 54-85-3, Isoniazid 55-10-7, Vanillylmandelic acid 56-40-6, Glycine, analysis 56-41-7, Alanine, analysis 56-54-2, Quinidine 56-73-5, Glucose-6-phosphate 56-75-7, Chloramphenicol 56-81-5, Glycerol, analysis 56-85-9, Glutamine, analysis 56-89-3, Cystine, analysis 57-00-1, Creatine 57-12-5, Cyanide, analysis 57-13-6, Urea, analysis 57-27-2, Morphine, analysis 57-41-0, Diphenylhydantoin 57-42-1, Meperidine 57-43-2, Amobarbital 57-48-7, Fructose, analysis 57-50-1, Sucrose, analysis 57-53-4, Meprobamate 57-83-0, Progesterone, analysis 57-88-5, Cholesterol, analysis 58-08-2, Caffeine, analysis 58-22-0, Testosterone 58-25-3, Chlordiazepoxide 58-55-9, Theophylline, analysis 58-86-6, Xylose, analysis 59-05-2, Methotrexate 59-23-4, Galactose, analysis 59-30-3, analysis 59-67-6, Niacin, analysis 60-18-4, Tyrosine, analysis 60-27-5, Creatinine 60-92-4, Cyclic AMP 61-90-5, Leucine, analysis 62-44-2, Phenacetin 63-05-8, Androstenedione 63-42-3, Lactose 63-68-3, Methionine, analysis 63-91-2, Phenylalanine, analysis 64-17-5, Ethanol, analysis 64-77-7, Tolbutamide 64-85-7, 11-Deoxycorticosterone 67-56-1, Methanol, analysis 68-60-0, Tetrahydrodeoxycortisol 68-96-2, 17-Hydroxyprogesterone 69-72-7D, Salicylic acid, derivs. 69-93-2, Uric acid, analysis 70-18-8, Glutathione, analysis 72-18-4, Valine, analysis 72-44-6, Methaqualone 72-69-5, Nortriptyline 73-32-5, Isoleucine, analysis 76-42-6, Oxycodone 76-57-3, Codeine 76-73-3, Secobarbital 76-74-4, Pentobarbital 76-75-5, Thiopental 76-99-3, Methadone 77-10-1, Phencyclidine 77-21-4, Glutethimide 77-41-8, Methsuximide 77-67-8, Ethosuximide 79-14-1, Glycolic acid, analysis 79-83-4, Pantothenic acid 81-25-4, Cholic acid 82-58-6, Lysergic acid 83-44-3, Deoxycholic acid 83-88-5, Riboflavin, analysis 86-34-0, Phensuximide 87-86-5, Pentachlorophenol 97-31-4, Normetanephrine 99-66-1, Valproic acid 103-90-2, Acetaminophen 107-21-1, Ethylene glycol, analysis 113-18-8, Ethchlorvynol 123-63-7, Paraldehyde 125-33-7, Primidone 125-64-4, Methyprylon 127-17-3, Pyruvic acid, analysis 137-58-6, Lidocaine 143-74-8, Phenolsulfonphthalein 145-13-1, Pregnenolone 152-58-9, 11-Deoxycortisol 298-46-4, Carbamazepine 299-42-3, Ephedrine 300-62-9, Amphetamine 302-04-5, Thiocyanate, analysis 302-17-0,

Chloral hydrate 306-08-1, Homovanillic acid 359-83-1, Pentazocine  
 438-60-8, Protriptyline 439-14-5, Diazepam 451-13-8, Homogentisic acid  
 466-99-9, Hydromorphone 469-62-5, Propoxyphene 487-90-1,  
 Porphobilinogen 521-18-6, Dihydrotestosterone 525-66-6, Propranolol  
 537-46-2, Methamphetamine 553-12-8, Protoporphyrin 555-30-6,  
 Methyldopa 591-81-1,  $\gamma$ -Hydroxybutyric acid 604-75-1, Oxazepam  
 635-65-4, Bilirubin, analysis 651-48-9, Dehydroepiandrosterone sulfate  
 846-49-1, Lorazepam 1098-45-9, Pregnanetriol 1319-82-0, Aminocaproic  
 acid 1330-20-7, Xylene, analysis 1393-25-5, Secretin 1403-66-3,  
 Gentamicin 1404-90-6, Vancomycin 1622-61-3, Clonazepam 1668-19-5,  
 Doxepin 3737-09-5, Disopyramide 4205-90-7, Clonidine 4429-04-3,  
 Fructosamine 4685-14-7, Paraquat 4697-36-3, Carbenicillin 5001-33-2,  
 Metanephrine 5817-39-0, Reverse triiodothyronine 6027-13-0,  
 Homocysteine 6893-02-3, Triiodothyronine 7439-89-6, Iron, analysis  
 7439-92-1, Lead, analysis 7439-93-2, Lithium, analysis 7439-95-4,  
 Magnesium, analysis 7439-97-6, Mercury, analysis 7439-98-7,  
 Molybdenum, analysis 7440-02-0, Nickel, analysis 7440-28-0, Thallium,  
 analysis 7440-47-3, Chromium, analysis 7440-57-5, Gold, analysis  
 7440-66-6, Zinc, analysis 7440-70-2, Calcium, analysis 7782-49-2,  
 Selenium, analysis 7783-06-4, Hydrogen sulfide, analysis 8063-07-8,  
 Kanamycin 9000-86-6, Alanine aminotransferase 9000-92-4, Amylase  
 9000-94-6, Antithrombin 9001-08-5, Pseudocholinesterase 9001-10-9,  
 Pepsinogen 9001-15-4, Creatine kinase 9001-58-5, Isocitrate  
 dehydrogenase 9001-62-1, Lipase 9001-63-2, Lysozyme 9001-77-8, Acid  
 phosphatase 9001-80-3, Phosphofructokinase 9001-91-6, Plasminogen  
 9002-60-2, Adrenocorticotrophic hormone, analysis 9002-61-3, Chorionic  
 gonadotropin 9002-64-6, Parathyroid hormone 9002-68-0, Follicle  
 stimulating hormone 9002-71-5, Thyroid stimulating hormone 9002-72-6,  
 Growth hormone 9002-76-0, Gastrin 9004-07-3, Chymotrypsin 9004-10-8,  
 Insulin, analysis 9007-12-9, Calcitonin 9007-92-5, Glucagon, analysis  
 9014-48-6, Transketolase 9015-94-5, Renin, analysis 9024-52-6,  
 Aldolase 9035-54-5, Placental lactogen 9035-68-1, Proinsulin  
 9035-81-8, Antitrypsin 11000-17-2, Antidiuretic hormone 11016-39-0,  
 Properdin 12794-10-4D, Benzodiazepine, derivs. 14797-65-0, Nitrite,  
 analysis 14838-15-4, Phenylpropanolamine 15687-27-1, Ibuprofen  
 17617-23-1, Flurazepam 20830-75-5, Digoxin 23887-31-2, Clorazepate  
 24305-27-9, Thyrotropin-releasing hormone 24959-67-9, Bromide, analysis  
 26316-36-9, Uroporphyrin 26445-07-8, Pregnanediol 27121-71-7,  
 Coproporphyrin 29679-58-1, Fenoprofen 32795-44-1,  $\alpha$ -Acetylprocainamide  
 32986-56-4, Tobramycin 37221-79-7, Vasoactive intestinal polypeptide  
 37517-28-5, Amikacin 39335-01-8, Macroamylase 51481-61-9, Cimetidine  
 54143-55-4, Flecainide 56391-56-1, Netilmicin 59112-80-0,  $\alpha$ -Peptide  
 59763-91-6, Pancreatic polypeptide 59865-13-3, Cyclosporine  
 67763-96-6, Somatomedin c 69776-17-6 85876-02-4, Glutamyltransferase  
 152923-57-4, Lutropin

RL: ANT (Analyte); ANST (Analytical study)

(method for assaying biomols. and other constituents using indicator  
 conjugates with synthetic nucleounits in lateral flow, liq., and dry  
 chem. techniques)

L93 ANSWER 4 OF 49 WPIX (C) 2003 THOMSON DERWENT

ACCESSION NUMBER: 2002-220563 [28] WPIX

DOC. NO. NON-CPI: N2002-169310

DOC. NO. CPI: C2002-067415

TITLE: Antiphospholipid antibody measuring reagent useful for  
 counting immunoassay comprises lipid antigen  
 sensitized on support by applying anti-stock solution

containing **phosphatidylcholine**,  
**cholesterol** and **cardiolipin**.

DERWENT CLASS: A14 A96 B04 J04 S03  
 PATENT ASSIGNEE(S): (TOAI-N) TOA IYO DENSHI KK  
 COUNTRY COUNT: 1  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 2001242171 A		20010907	(200228)*		6

## APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 2001242171 A		JP 2000-54904	20000229

PRIORITY APPLN. INFO: JP 2000-54904 20000229

AB JP2001242171 A UPAB: 20020502

NOVELTY - An antiphospholipid antibody measuring reagent comprises a lipid antigen sensitized on a support by applying 30-95 mg of an anti-stock solution per g of support. The anti-stock solution contains 2-15 times of **phosphatidylcholine**, 0-6 times of **cholesterol** and **cardiolipin**. The support is blocked by polyvinyl **alcohol**

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (a) manufacturing method of the antiphospholipid antibody measuring reagent; and
- (b) antiphospholipid antibody measuring method.

USE - For counting **immunoassay**.

ADVANTAGE - The antiphospholipid antibody measuring reagent correlates well with the conventional method such as RPR. A highly sensitive measurement is obtained by the reagent and the measurement can be automated.

Dwg.0/1

L93 ANSWER 5 OF 49 MEDLINE

ACCESSION NUMBER: 2002113011 MEDLINE

DOCUMENT NUMBER: 21835408 PubMed ID: 11846719

TITLE: Low HIV-seroprevalence in pregnant women in a rural area in Tanzania.

AUTHOR: Hinderaker S G; Kruger C; Olsen B E; Naman N; Bergsjo P; Olsen O H

CORPORATE SOURCE: Haydom Lutheran Hospital, Tanzania..  
 sven.hinderaker@cih.uib.no

SOURCE: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, (2001 Dec)  
 80 (12) 1152-3.

Journal code: 0370343. ISSN: 0001-6349.

PUB. COUNTRY: Denmark

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200203

ENTRY DATE: Entered STN: 20020216

Last Updated on STN: 20020313

Entered Medline: 20020312

CT Check Tags: Female; Human  
**Cardiolipins: BL, blood**  
 Cholesterol: BL, blood  
**Enzyme-Linked Immunosorbent Assay**  
 \*HIV: IP, isolation & purification  
 \*HIV Antibodies: BL, blood  
 HIV Infections: BL, blood  
 \*HIV Infections: EP, epidemiology  
**Phosphatidylcholines: BL, blood**  
 Pregnancy  
 Pregnancy Complications, Infectious: BL, blood  
 \*Pregnancy Complications, Infectious: EP, epidemiology  
 \*Pregnancy Complications, Infectious: VI, virology  
 Rural Population  
 Seroepidemiologic Studies  
**Syphilis: BL, blood**  
**Syphilis: EP, epidemiology**  
**Syphilis Serodiagnosis**  
 Tanzania: EP, epidemiology  
 RN 57-88-5 (Cholesterol)  
 CN 0 (Cardiolipins); 0 (HIV Antibodies); 0 (Phosphatidylcholines); 0 (VDRL antigen)

L93 ANSWER 6 OF 49 MEDLINE  
 ACCESSION NUMBER: 2001312322 MEDLINE  
 DOCUMENT NUMBER: 21279221 PubMed ID: 11384701  
 TITLE: Fetal syphilis: clinical and laboratory characteristics.  
 AUTHOR: Hollier L M; Harstad T W; Sanchez P J; Twickler D M; Wendel G D Jr  
 CORPORATE SOURCE: Departments of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA..  
 lisa.m.hollier@uth.tmc.edu  
 SOURCE: OBSTETRICS AND GYNECOLOGY, (2001 Jun) 97 (6) 947-53.  
 Journal code: 0401101. ISSN: 0029-7844.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
 ENTRY MONTH: 200106  
 ENTRY DATE: Entered STN: 20010625  
 Last Updated on STN: 20010625  
 Entered Medline: 20010621

AB OBJECTIVE: To examine the pathophysiology of fetal syphilis and correlate hematologic, immunologic, and sonographic findings. METHODS: Twenty-four women with untreated syphilis during pregnancy were prospectively identified. Sonography with amniocentesis and percutaneous umbilical blood sampling were performed. Darkfield examination, rabbit infectivity testing, and polymerase chain reaction for detection of *Treponema pallidum* were performed on amniotic fluid. Hematologic and chemical testing of fetal blood was performed using standard techniques. Fetal antitreponemal IgM was detected by Western blot assay. Maternal syphilis was treated with 2.4 to 4.8 million units of benzathine penicillin G intramuscularly. Neonatal outcomes and signs of congenital syphilis were recorded. RESULTS: Six women had primary, 12 had secondary, and six had early latent syphilis. Sixty-six percent of fetuses (95% confidence

interval [CI] 47%, 82%) had either congenital **syphilis** or **detection** of Treponema pallidum in amniotic fluid. Sixty-six percent had hepatomegaly, including three fetuses (12.5%, 95% CI 4%, 31%) with ascites. Fetal antitreponemal IgM was detected in three cases. Abnormal liver transaminases were found in 88% (CI 69%, 96%), anemia in 26% (CI 13%, 47%), and thrombocytopenia in 35% (CI 19%, 55%). Maternal treatment was successful in 83% (CI 64%, 93%). Risk of treatment failure was significantly increased when hepatomegaly and ascites were present ( $P = .01$ ). CONCLUSION: Findings with fetal syphilis are similar to those of neonatal syphilis. We hypothesize that fetal transaminase elevation occurs early in the course of infection; hematologic abnormalities and hydrops occur later. Severity of disease may be associated with risk of treatment failure.

CT Check Tags: Female; Human; Support, Non-U.S. Gov't  
Adult

Amniocentesis: MT, methods

**Cardiolipins: AN, analysis**

Cholesterol: AN, analysis

Confidence Intervals

\*Disease Transmission, Vertical

Fetal Blood: MI, microbiology

\*Fetal Diseases: DI, diagnosis

Follow-Up Studies

Incidence

Infant, Newborn

Injections, Intramuscular

Odds Ratio

Penicillin G: AD, administration & dosage

**Phosphatidylcholines: AN, analysis**

Pregnancy

\*Prenatal Diagnosis: MT, methods

Prospective Studies

Risk Factors

**\*Syphilis: DI, diagnosis**

Syphilis: DT, drug therapy

\*Syphilis: TM, transmission

**\*Syphilis, Congenital: DI, diagnosis**

Syphilis, Congenital: EP, epidemiology

Ultrasonography, Prenatal

RN 57-88-5 (Cholesterol); 61-33-6 (Penicillin G)

CN 0 (Cardiolipins); 0 (Phosphatidylcholines); 0 (VDRL antigen)

L93 ANSWER 7 OF 49 MEDLINE

ACCESSION NUMBER: 2001411803 MEDLINE

DOCUMENT NUMBER: 21354143 PubMed ID: 11460026

TITLE: Congenital syphilis and fluorescent treponemal antibody test reactivity after the age of 1 year.

AUTHOR: Rawstron S A; Mehta S; Marcellino L; Rempel J; Chery F; Bromberg K

CORPORATE SOURCE: Division of Pediatric Infectious Diseases, Department of Pediatrics, Children's Medical Center of Brooklyn, Kings County Hospital Center and SUNY Downstate, Brooklyn, New York 11203-2098, USA.

SOURCE: SEXUALLY TRANSMITTED DISEASES, (2001 Jul) 28 (7) 412-6.  
Journal code: 7705941. ISSN: 0148-5717

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

## (VALIDATION STUDIES)

LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200108  
 ENTRY DATE: Entered STN: 20010903  
 Last Updated on STN: 20010903  
 Entered Medline: 20010830

AB BACKGROUND: Many believe that a persistently reactive fluorescent treponemal antibody absorption (FTA-ABS) is manifested with congenital syphilis after the age of 1 year, that it is useful in the retrospective diagnosis of children with congenital syphilis, and that it can be used to confirm other treponemal tests. GOAL: To determine whether a reactive FTA-ABS after the age of 12 months is indicative of congenital syphilis. STUDY DESIGN: Prospective outpatient follow-up evaluation until at least the age of 12 months was conducted for 194 babies born to mothers with reactive syphilis serology at delivery, and for two additional children with congenital syphilis diagnosed when they were younger than 1 year (total, 196 children). RESULTS: In the study group, 54 children had reactive FTA-ABS (reactors) until the age of at least 12 months or more, and 142 children had nonreactive FTA-ABS (nonreactors) at the age of 12 months or more. Of the 54 reactors, 17 (31%) had evidence of congenital syphilis at birth, whereas evidence of congenital syphilis was seen in 14 of the 142 (10%) nonreactors ( $P = 0.0002$ ). At 15 months, nonreactive FTA-ABS developed in six reactors, and eventually in 15 of 44 reactors (34%) tested. CONCLUSIONS: A reactive FTA-ABS may be seen at 12 months in children with and without evidence of congenital syphilis at birth. Not all children with congenital syphilis will manifest reactive FTA-ABS at 12 months, and FTA-ABS reactivity wanes with time.

CT Check Tags: Human; Support, Non-U.S. Gov't

Age Factors

Blotting, Western

Cardiolipins: CF, cerebrospinal fluid

Cholesterol: CF, cerebrospinal fluid

Fluorescent Antibody Technique, Direct

\*Fluorescent Treponemal Antibody-Absorption Test: ST, standards

Follow-Up Studies

Hepatomegaly

Infant

Phosphatidylcholines: CF, cerebrospinal fluid

Sensitivity and Specificity

Splenomegaly

Syphilis, Congenital: BL, blood

Syphilis, Congenital: CF, cerebrospinal fluid

\*Syphilis, Congenital: DI, diagnosis

Syphilis, Congenital: IM, immunology

Time Factors

RN 57-88-5 (Cholesterol)

CN 0 (Cardiolipins); 0 (Phosphatidylcholines); 0 (VDRL antigen)

L93 ANSWER 8 OF 49 MEDLINE

ACCESSION NUMBER: 2001683747 MEDLINE

DOCUMENT NUMBER: 21586798 PubMed ID: 11729394

TITLE: [The role of yaws in the serologic screening of treponematoses in blood donors in Martinique].

La place du pian dans le dépistage sérologique des treponematoses chez les donneurs de sang de la Martinique.

AUTHOR: Maier H; Cesaire R; Bera O; Kerob-Bauchet B; Ould Amar A K;

CORPORATE SOURCE: Desbois N; Follea G  
 Etablissement francais du sang, hopital Pierre-Zobda  
 Quitman, BP 666, 97261, Fort-de-France, Martinique.  
 SOURCE: TRANSFUSION CLINIQUE ET BIOLOGIQUE, (2001 Oct) 8 (5) 403-9.  
 Journal code: 9423846. ISSN: 1246-7820.  
 PUB. COUNTRY: France  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: French  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200201  
 ENTRY DATE: Entered STN: 20011204  
 Last Updated on STN: 20020125  
 Entered Medline: 20020114

AB Using TPHA instead of VDRL for syphilis blood-screening since 1995 showed an important increase of positive blood donors in Martinique. Yaws, another treponema disease, has been present on the island until 1975-1980. Usual tests are unable to identify which type--venereal or non venereal--of treponema is involved. Our study, carried out from January 1995 to May 1999, compares actual serological and epidemiological characteristics of TPHA reactive donors to former studies. In our results, the frequency of reactive TPHA is about 1.04% in blood donations. Donors are carrying serological tracks of a past treponema disease with very low rate of antibodies, sometimes linked to yaws. Among donors aged 18 to 30, prevalence is low and is going to become similar to the rate observed in Continental France. This means that this problem will disappear in new donor generations. We suggest the possibility for them to continue blood donation, if their personal preliminary enquiry fits the admission criteria for blood giving.

CT Check Tags: Animal; Comparative Study; Female; Human; Male

Adolescent

Adult

Age Distribution

Aged

Antibodies, Protozoan: BL, blood

\*Blood Donors: SN, statistics & numerical data

Cardiolipins: BL, blood

Cholesterol: BL, blood

Cross Reactions

Diagnosis, Differential

English Abstract

\*Hemagglutination Tests

Martinique: EP, epidemiology

\*Mass Screening: SN, statistics & numerical data

Middle Age

Morbidity: TD, trends

Phosphatidylcholines: BL, blood

Prospective Studies

Retrospective Studies

Seroepidemiologic Studies

Species Specificity

\*Syphilis: DI, diagnosis

Syphilis: EP, epidemiology

Syphilis: PC, prevention & control

\*Syphilis Serodiagnosis

Syphilis Serodiagnosis: MT, methods

Treponema pallidum: IM, immunology

\*Yaws: DI, diagnosis

RN Yaws: EP, epidemiology  
 RN 57-88-5 (Cholesterol)  
 CN 0 (Antibodies, Protozoan); 0 (Cardiolipins); 0 (Phosphatidylcholines); 0  
 (VDRL antigen)

L93 ANSWER 9 OF 49 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 1  
 ACCESSION NUMBER: 2000:881429 HCAPLUS  
 DOCUMENT NUMBER: 134:41088  
 TITLE: Method for detecting syphilis using synthetic antigens  
 INVENTOR(S): Pope, Victoria; Castro, Arnold R.; Morrill, William E.  
 PATENT ASSIGNEE(S): Government of the United States of America,  
 Represented by the Secretary, De, USA  
 SOURCE: PCT Int. Appl., 34 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION: *Priority of*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075666	A1	20001214	WO 2000-US15828	20000608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1185872	A1	20020313	EP 2000-939708	20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000011449	A	20020319	BR 2000-11449	20000608
JP 2003501662	T2	20030114	JP 2001-501890	20000608
PRIORITY APPLN. INFO.:			US 1999-138192P P	19990609
			WO 2000-US15828 W	20000608

AB An antigen compn. and method for the detection of antibodies to *Treponema pallidum* and the diagnosis of syphilis are described. The antigen compn. contains synthetic cardiolipin and synthetic lecithin. The antigen compn. may addnl. contain cholesterol and an alc. The antigen compn. is useful as an immunoreagent in immunoassays for the detection of antibodies assocd. with *T. pallidum* infection. The methods are sensitive and specific for *T. pallidum* infection.

IC ICM G01N033-571  
 ICS G01N033-92

CC 15-1 (Immunochemistry)

IT **Immunoassay**  
 (agglutination test; method for detecting syphilis using synthetic antigens)

IT Biological materials  
 Blood analysis  
**Diagnosis**  
**Immunoassay**  
**Syphilis**  
**Treponema pallidum**

IT (method for detecting syphilis using synthetic antigens)  
**Antigens**  
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (method for detecting syphilis using synthetic antigens)

IT **Alcohols, analysis**  
 RL: ARU (Analytical role, unclassified); ANST (Analytical study)  
 (method for detecting syphilis using synthetic antigens)

IT **Cardiolipins**  
 Phosphatidylcholines, biological studies  
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (synthetic, in antigen compn.; method for detecting syphilis using synthetic antigens)

IT **Cardiolipins**  
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (tetramyristoyl-; method for detecting syphilis using synthetic antigens)

IT **57-88-5, Cholesterol, biological studies 26853-31-6,**  
 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine  
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (method for detecting syphilis using synthetic antigens)

IT **64-17-5, Ethanol, analysis**  
 RL: ARU (Analytical role, unclassified); ANST (Analytical study)  
 (method for detecting syphilis using synthetic antigens)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L93 ANSWER 10 OF 49 HCPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2000:133425 HCPLUS  
 DOCUMENT NUMBER: 132:171128  
 TITLE: A novel liposomal formulation useful in treatment of cancer and other proliferation diseases  
 INVENTOR(S): Gupta, Suresh Kumar; Sengupta, Shiladitya; Velpandian, Thirumurthy  
 PATENT ASSIGNEE(S): All India Institute of Medical Sciences, India  
 SOURCE: PCT Int. Appl., 56 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009071	A2	20000224	WO 1999-IN37	19990810
WO 2000009071	A3	20000615		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
AU 2000016789	A1	20000306	AU 2000-16789	19990810
PRIORITY APPLN. INFO.:			IN 1998-DE2337	A 19980811
			WO 1999-IN37	W 19990810

AB The present invention relates to a novel liposomal formulation useful in the treatment of cancer and other proliferative diseases, with enhanced stability, efficacy and reduced toxicity profile, said formulation comprising a mixt. of at least epipodophyllotoxin or its analogs or derivs., phospholipids, sterols, antioxidants and cryoprotectants, and also provides liposomal kit using said formulation, as well as a process for prepn. of such formulations and a method of treatment of animals including humans using such formulations. Thus, liposomes were prep'd. by a thin-film hydration method followed by extrusion. The lipid components were weighed and dissolved in chloroform at the desired molar ratio. For the synthesis of pos. charged liposomes, the lipid components taken were lecithin, cholesterol, stearylamine and tocopherol in the molar ratio of 7:2:2:1. To find out the encapsulation efficiency initial expts. were carried out by keeping either total lipid concn. const. and varying the drug concn. or vice-versa. The optimum lipid drug ratio which yielded max. encapsulation was selected for further studies. The drug was dissolved in chloroform and methanol (1:1) and then added to the lipids dissolved in chloroform in the desired molar ratios. The lipid drug film was formed by flash rotary evapn. under nitrogen by using a round bottom flask with glass beads to increase the surface area. The coating was then lyophilized and stored under vacuum for 12 h. It was then hydrated with pH 7.4 phosphate buffer saline by vigorous vortexing. The liposomes thus formed 20 were of multilamellar vesicular nature. These liposomes were then repeatedly extruded through double stacked polycarbonate membranes with pore diam. 100 nm using a high pressure extrusion. This leads to synthesis of unilamellar vesicles of small diam. (100 nm). The free drug was then sepd. from the liposome encapsulated component by passing it through a Sephadex G-column and subsequent centrifugation at 10.000 G for 15 min under which conditions the liposomes remain suspended and etoposide ppts. are sedimented.

IC ICM A61K

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

IT **Cardiolipins**

Cerebrosides

Chelates

Flavonoids

**Lecithins**

Lysophosphatidylcholines

Lysophosphatidylethanolamines

Peptides, biological studies

Phosphatidic acids

Phosphatidylcholines, biological studies

Phosphatidylethanolamines, biological studies

Phosphatidylglycerols

Phosphatidylinositols

Phosphatidylserines

Phospholipids, biological studies

Polyoxyalkylenes, biological studies

Quinones

Sphingomyelins

Sterols

Tocopherols

Ubiquinones

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(liposomal formulation in treatment of cancer and other proliferation diseases)

IT 64-17-5, Ethanol, uses 67-56-1, Methanol, uses 67-66-3, uses 71-43-2, Benzene, uses 75-65-0, uses 111-87-5, Octanol, uses  
 RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PROC (Process); USES (Uses)  
 (liposomal formulation in treatment of cancer and other proliferation diseases)

IT 56-81-5, 1,2,3-Propanetriol, biological studies 57-50-1, biological studies 57-88-5, Cholesterol, biological studies 67-68-5, DMSO, biological studies 69-65-8, Mannitol 70-18-8, Glutathione, biological studies 99-20-7, Trehalose 124-30-1, Stearylamine 127-17-3D, Pyruvic acid, derivs. 2644-64-6, DiPalmitoylphosphatidylcholine 3458-28-4, Mannose 4537-77-3, Dipalmitoylphosphatidylglycerol 4537-78-4, Distearoylphosphatidylglycerol 1 4539-70-2, Distearoylphosphatidylcholine 5681-36-7, DiPalmitoylphosphatidylethanolamine 7235-40-7, .beta.-Carotene 10589-48-7 10589-50-1 12001-76-2, Vitamin B 18656-38-7, Dimyristoylphosphatidylcholine 18656-40-1, Dilauroylphosphatidylcholine 19698-29-4, Dipalmitoylphosphatidic acid 20255-95-2, DiMyristoylphosphatidylethanolamine 25322-68-3 30170-00-4, Dimyristoylphosphatidic acid 61361-72-6, Dimyristoylphosphatidylglycerol 62700-69-0, Dioleoylphosphatidylglycerol 63119-37-9 63644-55-3, Dilauroylphosphatidylglycerol 64023-32-1 68737-67-7, Dioleoylphosphatidylcholine 78003-52-8 127512-29-2 145035-96-7 145191-86-2, Dioleyldimethyl ammonium chloride 183283-20-7 259140-41-5 259140-42-6  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (liposomal formulation in treatment of cancer and other proliferation diseases)

L93 ANSWER 11 OF 49 HCPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2000:32433 HCPLUS  
 DOCUMENT NUMBER: 132:63139  
 TITLE: A reagent for measuring anti-phospholipid antibody to detect Treponema Pallidum infection  
 INVENTOR(S): Ota, Tetsuya  
 PATENT ASSIGNEE(S): Sekisui Chemical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000009731	A2	20000114	JP 1998-173221	19980619
PRIORITY APPLN. INFO.:			JP 1998-173221	19980619

AB A reliable and convenient reagent is provided for measuring anti-phospholipid antibody to detect Treponema Pallidum infection. The reagent makes it practical to rapidly measure anti-phospholipid antibody in a large quantity of samples as it is applied to an automated biochem. analyzer. The reagent for measuring anti-phospholipid antibody is obtained by immobilizing the phospholipid antigen consisting of cardiolipin, lecithin and cholesterol onto the insol. carrier (e.g., Formaldehyde is added at 0.01-1% (w/v) to the insol. carrier holding the lipid antigen. antibody in test samples was measured with a high

sensitivity by agglutination turbidimetry using this reagent.

IC ICM G01N033-531  
 ICS G01N033-53  
 CC 15-1 (Immunochemistry)  
 Section cross-reference(s): 14  
 IT **Immunoassay**  
 (agglutination test; reagent for measuring anti-phospholipid antibody to detect *Treponema Pallidum* infection)  
 IT **Immunoassay**  
 (app., automated; reagent for measuring anti-phospholipid antibody to detect *Treponema Pallidum* infection)  
 IT Immobilization, biochemical  
 Infection  
 Latex  
**Treponema pallidum**  
 Turbidimetry  
 (reagent for measuring anti-phospholipid antibody to detect *Treponema Pallidum* infection)  
 IT **Cardiolipins**  
**Lecithins**  
 Phospholipids, uses  
 RL: ARG (Analytical reagent use); PEP (Physical, engineering or chemical process); ANST (Analytical study); PROC (Process); USES (Uses)  
 (reagent for measuring anti-phospholipid antibody to detect *Treponema Pallidum* infection)

L93 ANSWER 12 OF 49 MEDLINE DUPLICATE 2  
 ACCESSION NUMBER: 2000425594 MEDLINE  
 DOCUMENT NUMBER: 20342558 PubMed ID: 10882668  
 TITLE: Use of synthetic cardiolipin and lecithin in the antigen used by the venereal disease research laboratory test for serodiagnosis of syphilis.  
 AUTHOR: Castro A R; Morrill W E; Shaw W A; Gale D C; Park M M; Peregrino-Ferreira L A; Bazzo M L; Pope V  
 CORPORATE SOURCE: Division of AIDS, STD, and TB Laboratory Research, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.. ajc5@cdc.gov  
 SOURCE: CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, (2000 Jul) 7 (4) 658-61.  
 Journal code: 9421292. ISSN: 1071-412X.

PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200009  
 ENTRY DATE: Entered STN: 20000922  
 Last Updated on STN: 20000922  
 Entered Medline: 20000912

AB The Venereal Disease Research Laboratory (VDRL) test is a microflocculation test for syphilis that uses an antigen containing cardiolipin, lecithin, and cholesterol. For more than 50 years, the preparation of natural cardiolipin and lecithin for this test has been based on the Pangborn method which involves isolating and purifying these components from beef hearts. This process is tedious and time-consuming and results in a variable purity range. In our studies, we found that a VDRL antigen using synthetic tetramyristoyl cardiolipin and synthetic 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (lecithin) was as

specific in **detecting syphilis** as a VDRL antigen made with natural components. In 85% of the cases, we obtained an endpoint titer of 1/2 or 1 dilution more than a titer obtained with a VDRL antigen made with natural components. The use of these pure synthetic compounds, with a purity of 99%, would offer advantages in the standardization and stability of the VDRL antigen. Because this antigen is the basic ingredient in the preparation of nontreponemal reagents such as the rapid plasma reagin, toluidine red unheated serum test, and the unheated serum reagin, the use of this synthetic VDRL antigen should also increase the reactivity of these reagents.

CT Check Tags: Human

Cardiolipins: CH, chemistry

\*Cardiolipins: DU, diagnostic use

Phosphatidylcholines: CH, chemistry

\*Phosphatidylcholines: DU, diagnostic use

Sensitivity and Specificity

\*Syphilis: DI, diagnosis

\*Syphilis Serodiagnosis: MT, methods

CN 0 (Cardiolipins); 0 (Phosphatidylcholines)

L93 ANSWER 13 OF 49 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2001053987 EMBASE

TITLE: Biochemical effects of the hill-growing saltwort on some parameters of metabolism in rat cerebellum upon ethanol administration and withdrawal.

AUTHOR: Selevich M.I.; Lelevich V.V.; Vinitskaya A.G.; Kozlovskii A.V.; Doroshenko E.M.; Razvadovskii Yu.E.; Chirkin A.A.; Danchenko E.O.

CORPORATE SOURCE: M.I. Selevich, Grodno State Medical Institute, Grodno, Belarus

SOURCE: Pharmaceutical Chemistry Journal, (2000) 34/6 (307-309).  
Refs: 13

COUNTRY: ISSN: 0091-150X CODEN: PCJOAU

DOCUMENT TYPE: United States

FILE SEGMENT: Journal; Article

008 Neurology and Neurosurgery  
030 Pharmacology  
052 Toxicology  
029 Clinical Biochemistry  
005 General Pathology and Pathological Anatomy  
037 Drug Literature Index

LANGUAGE: English

CT Medical Descriptors:

\*brain metabolism

\*alcohol intoxication: ET, etiology

\*alcohol withdrawal: ET, etiology

controlled study

nonhuman

rat

animal experiment

animal model

animal tissue

male

drug effect

cerebellum

drug screening

brain homogenate

enzyme activity  
 biochemistry  
 lipid metabolism  
 liver protection  
 energy metabolism  
 carbohydrate metabolism  
 lipid brain level  
 lipid composition  
 article

## Drug Descriptors:

\*salsocollin: DV, drug development  
 \*salsocollin: IG, intragastric drug administration  
 \*salsocollin: PD, pharmacology  
 \*Salsola collina extract: DV, drug development  
 \*Salsola collina extract: IG, intragastric drug administration  
 \*Salsola collina extract: PD, pharmacology  
 \*plant extract: DV, drug development  
 \*plant extract: IG, intragastric drug administration  
 \*plant extract: PD, pharmacology

## \*alcohol

lipid: EC, endogenous compound

## cholesterol: EC, endogenous compound

phospholipid: EC, endogenous compound

serine: EC, endogenous compound

phosphoethanolamine: EC, endogenous compound

succinate dehydrogenase: EC, endogenous compound

lactate dehydrogenase: EC, endogenous compound

malate dehydrogenase: EC, endogenous compound

alanine aminotransferase: EC, endogenous compound

aspartate aminotransferase: EC, endogenous compound

sphingomyelin: EC, endogenous compound

## phosphatidylcholine: EC, endogenous compound

## cardiolipin: EC, endogenous compound

unclassified drug

RN (alcohol) 64-17-5; (lipid) 66455-18-3; (cholesterol) 57-88-5; (serine) 56-45-1, 6898-95-9; (phosphoethanolamine) 1071-23-4, 29868-05-1; (succinate dehydrogenase) 9002-02-2, 9028-10-8; (lactate dehydrogenase) 9001-60-9; (malate dehydrogenase) 9001-64-3; (alanine aminotransferase) 9000-86-6, 9014-30-6; (aspartate aminotransferase) 9000-97-9; (sphingomyelin) 85187-10-6; (phosphatidylcholine) 55128-59-1, 8002-43-5

L93 ANSWER 14 OF 49 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:133628 HCAPLUS

DOCUMENT NUMBER: 130:179408

TITLE: Administrable compositions and methods for magnetic resonance imaging

INVENTOR(S): Tournier, Herve; Schneider, Michel; Yan, Feng;

Brochot, Jean

PATENT ASSIGNEE(S): Bracco Research S.A., Switz.

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 9907415	A1	19990218	WO 1998-IB1227	19980811
W: AU, CA, CN, IL, JP, KR, MX, NO, RU				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9884587	A1	19990301	AU 1998-84587	19980811
AU 726115	B2	20001102		
EP 968000	A1	20000105	EP 1998-935248	19980811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001501977	T2	20010213	JP 1999-511918	19980811
IL 129173	A1	20020310	IL 1998-129173	19980811
CN 1103605	B	20030326	CN 1998-801143	19980811
NO 9901688	A	19990609	NO 1999-1688	19990409
PRIORITY APPLN. INFO.:			EP 1997-810563	A 19970812
			WO 1998-IB1227	W 19980811

AB The invention relates to the application of hyperpolarized gases to magnetic resonance imaging (MRI) of living subjects. The invention also concerns administrable compns., formulations, methods of making the compns. and formulations and contrast agents involving hyperpolarized gases, as well as their use in MRI.

IC ICM A61K049-00

CC 8-9 (Radiation Biochemistry)

Section cross-reference(s): 9

IT Carbohydrates, biological studies

**Cardiolipins**

Fatty acids, biological studies

Hydrocarbons, biological studies

**Lecithins**

Oligosaccharides, biological studies

Perfluoro compounds

Phosphatidic acids

Phosphatidylcholines, biological studies

Phosphatidylethanolamines, biological studies

Phosphatidylglycerols

Phosphatidylinositols

Phosphatidylserines

Phospholipids, biological studies

Polyanhydrides

Polyesters, biological studies

Polymers, biological studies

Polyoxyalkylenes, biological studies

Polyphosphazenes

Polysaccharides, biological studies

Proteins, general, biological studies

Sitosterols

Sphingomyelins

Tocopherols

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. and methods using hyperpolarized gas and halogenated gas for MRI)

IT **Alcohols, biological studies**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fatty acid esters; compns. and methods using hyperpolarized gas and halogenated gas for MRI)

IT **Alcohols, biological studies**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(polyhydric, fatty acid esters; compns. and methods using

IT hyperpolarized gas and halogenated gas for MRI)  
 56-81-5D, Glycerol, polyalkylenated 57-87-4, Ergosterol 57-88-5  
 , Cholest-5-en-3-ol (3. $\beta$ .)-, biological studies 75-73-0 76-16-4,  
 Hexafluoroethane 76-19-7 79-63-0, Lanosterol 116-14-3, biological  
 studies 116-15-4 121-79-9, Propyl gallate 128-37-0, Butylated  
 hydroxytoluene, biological studies 137-66-6, Ascorbyl palmitate  
 355-25-9 355-42-0 360-89-4 376-77-2 678-26-2 685-63-2  
 2197-63-9, Dicetyl phosphate 4537-77-3, Dipalmitoylphosphatidylglycerol  
 4539-70-2 7439-90-9, Krypton, biological studies 7440-37-1, Argon,  
 biological studies 7440-59-7, Helium, biological studies 7440-63-3,  
 Xenon, biological studies 14683-11-5, Xenon-131, biological studies  
 14762-55-1, Helium-3, biological studies 19698-29-4,  
 Dipalmitoylphosphatidic acid 24991-23-9D, derivs. and copolymers  
 25322-68-3 25513-46-6D, Polyglutamic acid, derivs. and copolymers  
 25608-40-6D, Polyaspartic acid, derivs. and copolymers 26009-03-0,  
 Polyglycolide 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)]  
 26063-13-8D, Polyaspartic acid, derivs. and copolymers 26202-08-4,  
 Polyglycolide 26680-10-4, Polylactide 26780-50-7, Lactide-glycolide  
 copolymer 31621-87-1, Polydioxanone 83061-18-1,  
 Diarachidoylphosphatidylcholine 106392-12-5, Polyoxyethylene-  
 polyoxypropylene block copolymer  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (compns. and methods using hyperpolarized gas and halogenated gas for  
 MRI)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L93 ANSWER 15 OF 49 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:610558 HCAPLUS

DOCUMENT NUMBER: 131:227651

TITLE: Reagents for measuring anti-phospholipid antibodies

INVENTOR(S): Ota, Tetsuya

PATENT ASSIGNEE(S): Sekisui Chemical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11258236	A2	19990924	JP 1998-56816	19980309
PRIORITY APPLN. INFO.:			JP 1998-56816	19980309

AB Highly sensitive and objective reagents applicable to a general biochem. automated analyzer are provided for rapidly and conveniently measuring anti-phospholipid antibodies in many blood samples. Lipid antigen consisting of cardiolipin and lecithin is immobilized on insol. carrier preferably through denatured serum albumin such as alkylated serum albumin. The lipid antigen is immobilized on the insol. carrier on which is immobilized beforehand. In an alternative method, is immobilized on the insol. carrier after its complex is formed. A certain amt. of cardiolipin and is immobilized on latex through methylated serum albumin by successfully applied to measure antibodies to Treponema species.

CC ICS G01N033-53; G01N033-571; G01N033-92  
 15-1 (Immunochemistry)  
 Section cross-reference(s): 10, 14  
 IT **Immunoassay**  
 (app., automated; reagents for measuring anti-phospholipid antibodies)  
 IT **Immunoassay**  
 (latex agglutination test; reagents for measuring anti-phospholipid antibodies)  
 IT Blood analysis  
**Treponema pallidum**  
 (reagents for measuring anti-phospholipid antibodies)  
 IT **Cardiolipins**  
**Lecithins**  
 RL: ARG (Analytical reagent use); PEP (Physical, engineering or chemical process); ANST (Analytical study); PROC (Process); USES (Uses)  
 (reagents for measuring anti-phospholipid antibodies)

L93 ANSWER 16 OF 49 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:296705 HCAPLUS  
 DOCUMENT NUMBER: 130:336962  
 TITLE: Method for preparing reagent for detection of  
 anti-phospholipid antibody  
 INVENTOR(S): Ohta, Tetsuya  
 PATENT ASSIGNEE(S): Sekisui Chemical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11118800	A2	19990430	JP 1997-283845	19971016
JP 1997-283845 19971016				
PRIORITY APPLN. INFO.:				
AB	The disclosed test reagent comprises synthetic polymer-immobilized lipid antigen. The synthetic polymer carrier is latex, and the immobilized antigen comprises cardiolipin, lecithin and cholesterol. The latex-immobilized cardiolipin and lecithin and cholesterol is suitable for detecting anti-phospholipid autoantibodies by automated analyzer system, and is therefore useful for diagnosing Treponema pallidum infection as well as systemic lupus erythematosus and other autoimmune diseases.			
IC	ICM G01N033-531			
CC	ICS G01N033-545; G01N033-92 15-3 (Immunochemistry)			
IT	<b>Immunoassay</b> (app., automatic; method for prep. reagent for detection of anti-phospholipid antibody)			
IT	<b>Treponema pallidum</b> (inf method for prep. reagent for detection of anti antibody)			
IT	<b>Cardiolipins</b> <b>Lecithins</b> RL: A stud e); THU (Therapeutic use); ANST (Analytical y); USES (Uses) for detection of anti-phospholipid antibody)			

L93 ANSWER 17 OF 49 MEDLINE  
 ACCESSION NUMBER: 1999379950 MEDLINE  
 DOCUMENT NUMBER: 99379950 PubMed ID: 10449935  
 TITLE: A prospective study of the influence of HIV status on the seroreversion of serological tests for syphilis.  
 AUTHOR: Janier M; Chastang C; Spindler E; Strazzi S; Rabian C; Marcelli A; Morel P  
 CORPORATE SOURCE: Sexually Transmitted Diseases Clinic, Hopital Saint-Louis, Paris, France.  
 SOURCE: DERMATOLOGY, (1999) 198 (4) 362-9.  
 Journal code: 9203244. ISSN: 1018-8665.  
 PUB. COUNTRY: Switzerland  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals; AIDS  
 ENTRY MONTH: 199909  
 ENTRY DATE: Entered STN: 19990925  
 Last Updated on STN: 19990925  
 Entered Medline: 19990915

AB The evolution of serological tests for syphilis (STSs) after therapy in HIV+ patients is a major point of controversy, with possible seroreactivation and illicit seroreversion in these patients. The aim of our study was to evaluate the long-term outcome of STSs in a cohort of HIV+ male homosexuals with a history of treated syphilis as compared with HIV- controls. PATIENTS AND METHODS: Sixty-nine HIV+ male homosexuals with a documented history of treated syphilis and positive baseline treponemal tests were prospectively studied between 1986 and 1993. A medical examination, HIV staging, CD4+ cell count, VDRL, FTA-Abs tests and TPHA were performed every 6 months. Controls consisted of 49 HIV- patients with similar inclusion criteria over the same period. Comparisons between subgroups were based on chi(2) and Kruskal-Wallis tests. Analysis of negativation of the STS used the failure data methods (Kaplan-Meier, log-rank and Cox's model). RESULTS: Patients had a mean age of 38 years, a baseline CD4+ cell count of 578/mm(3), elapsed time since last syphilis of 7.5 years and a median follow-up of 4.3 years. Controls had a mean age of 42 years, elapsed time since last syphilis of 5.3 years and a median follow-up of 4.7 years. Time to seroreversion was shorter in HIV+ patients for TPHA ( $p = 0.009$ , log-rank test) and FTA-Abs test ( $p = 0.001$ , log-rank test), even after adjustment for stage of syphilis, age and time since the last episode of syphilis. The decrease in VDRL titres was not different between the 2 groups ( $p = 0.053$ , log-rank test). Seroreversion of the TPHA, FTA-Abs test and VDRL test was not significantly related to stage of syphilis, time elapsed since the last episode of syphilis, age or history of STDs in both groups. Seroreversion of the TPHA and VDRL test was not related to baseline CD4+ cell count. However, seroreversion of the FTA-Abs test was related to a low baseline CD4+ cell count ( $p = 0.003$ ). In HIV+ patients, a significant decrease in titres was noticed for TPHA, FTA-Abs test and VDRL test over time, but this time effect remained only for TPHA titres after adjustment for the CD4+ cell count. CONCLUSION: TPHA may serorevert in HIV+ patients. Thus, a non-reactive TPHA does not exclude a past syphilis infection in such patients. Evolution of the VDRL test after therapy is regular in HIV+ patients. The VDRL test remains adequate for controlling the efficacy of treatment in these patients.

CT Check Tags: Comparative Study; Human; Male  
 Adult

CD4 Lymphocyte Count

**Cardiolipins: IM, immunology**  
**Cholesterol: IM, immunology**  
**Cohort Studies**

**Fluorescent Treponemal Antibody-Absorption Test**

HIV Seronegativity  
 \*HIV Seropositivity: BL, blood

**Hemagglutination Tests**

Homosexuality, Male  
 Middle Age

**Phosphatidylcholines: IM, immunology**

Prospective Studies

**\*Serologic Tests**

**\*Syphilis: IM, immunology**

Syphilis Serodiagnosis: MT, methods

Syphilis Serodiagnosis: ST, standards

Time Factors

RN 57-88-5 (Cholesterol)

CN 0 (Cardiolipins); 0 (Phosphatidylcholines); 0 (VDRL antigen)

L93 ANSWER 18 OF 49 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:595968 HCAPLUS

DOCUMENT NUMBER: 129:257361

TITLE: Manufacture of reagents for measuring phospholipid antibodies

INVENTOR(S): Oota, Tetsuya; Yoshikawa, Katsumi

PATENT ASSIGNEE(S): Sekisui Chemical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

**PATENT INFORMATION:**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10239315	A2	19980911	JP 1997-175797	19970701
PRIORITY APPLN. INFO.:			JP 1996-347987	19961226

AB A reagent is prep'd. for measuring phospholipid antibody that may be used for detection of syphilis. The lipid antigen consists of cardiolipin, lecithin, and cholesterol, and the antigen is bound to an insol. carrier. The relative amts. of the antigen components are cardiolipin 0.01-1.0 .mu.g, lecithin 3-15 fold of cardiolipin, and cholesterol 0-5 fold of cardiolipin against 10 .mu.g of the insol. carrier. The reaction temp. is 30-55.degree., and the reaction time is 1-10 h.

IC ICM G01N033-531

ICS G01N033-53; G01N033-571

CC 9-15 (Biochemical Methods)

Section cross-reference(s): 15

IT **Cardiolipins**

**Lecithins**


RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (in reagents for measuring phospholipid antibodies for syphilis detection)

IT **Antibodies**

**Antigens**

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (reagents for measuring phospholipid antibodies for syphilis detection)

L93 ANSWER 19 OF 49 MEDLINE  
 ACCESSION NUMBER: 1998126217 MEDLINE  
 DOCUMENT NUMBER: 98126217 PubMed ID: 9466741  
 TITLE: Evaluation of a new competitive immunoassay (BioElisa Syphilis) for screening for *Treponema pallidum* antibodies at various stages of syphilis.  
 AUTHOR: Ebel A; Bachelart L; Alonso J M  
 CORPORATE SOURCE: Institut Alfred Fournier, French National Reference Center for Sexually Transmitted Diseases, World Health Organization Collaborating Center for Treponematoses, Paris.  
 SOURCE: JOURNAL OF CLINICAL MICROBIOLOGY, (1998 Feb) 36 (2) 358-61.  
 Journal code: 7505564. ISSN: 0095-1137.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals; AIDS  
 ENTRY MONTH: 199804  
 ENTRY DATE: Entered STN: 19980416  
 Last Updated on STN: 19990129  
 Entered Medline: 19980406



AB The BioElisa Syphilis, a new competitive enzyme immunoassay (EIA) for *Treponema pallidum* whole antigen that uses specific human immunoglobulin G (IgG) antibodies as the competitor, was evaluated for potential use in screening for syphilis at various stages. The results obtained by this competitive EIA were compared with those obtained by the fluorescent treponemal antibody absorption (FTA-abs) test and the *T. pallidum* hemagglutination assay (TPHA). Serum samples from 434 patients with positive TPHA and FTA-abs test results, including patients with primary, latent, secondary, and tertiary syphilis and neurosyphilis, were investigated. Two samples tested negative by competitive EIA but were weakly reactive by the TPHA and the FTA-abs test. Sixteen serum samples from patients with clinically documented active syphilis, including several patients infected with human immunodeficiency virus, tested positive by the competitive EIA. There was a direct inverse correlation between EIA indices and titers in the TPHA and the FTA-abs test for all samples that tested positive. Specificity was assessed by testing 358 serum samples which tested negative for syphilis by TPHA and the FTA-abs test, including 100 serum samples from patients with documented infectious or autoimmune diseases. Only two serum samples gave a weakly positive EIA result. Thus, competitive EIA had a sensitivity of 99.5% and a specificity of 99.4% relative to the results of the FTA-abs test and TPHA. Our evaluation shows that BioElisa Syphilis is a sensitive, specific, and simple assay for screening for syphilis.

CT Check Tags: Comparative Study; Human  
 Antibodies, Bacterial: IM, immunology  
 \*Antibodies, Bacterial: IP, isolation & purification  
 Antigens, Bacterial: IM, immunology  
 Cardiolipins: AN, analysis  
 Cholesterol: AN, analysis  
 Fluorescent Treponemal Antibody-Absorption Test  
 Hemagglutination Tests  
 \*Immunoenzyme Techniques  
 Immunoglobulin G: IM, immunology  
 Immunoglobulin G: IP, isolation & purification  
 Immunoglobulin M: AN, analysis

**Phosphatidylcholines: AN, analysis**  
 Sensitivity and Specificity  
 Seroepidemiologic Studies  
 \***Syphilis Serodiagnosis: MT, methods**  
**Treponema pallidum: IM, immunology**  
 \***Treponema pallidum: IP, isolation & purification**

RN 57-88-5 (Cholesterol)  
 CN 0 (Antibodies, Bacterial); 0 (Antigens, Bacterial); 0 (Cardiolipins); 0 (Immunoglobulin G); 0 (Immunoglobulin M); 0 (Phosphatidylcholines); 0 (VDRL antigen)

L93 ANSWER 20 OF 49 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:756981 HCPLUS

DOCUMENT NUMBER: 128:39579

TITLE: Delivery of biologically active material in a liposomal formulation for administration into the mouth

INVENTOR(S): Keller, Brian C.; Fisher, Daniel L.; Kiss, Steven

PATENT ASSIGNEE(S): Biozone Laboratories, Inc., USA

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9742938	A1	19971120	WO 1997-US6618	19970421
W: CA, JP, YU				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5891465	A	19990406	US 1996-645894	19960514
EP 928189	A1	19990714	EP 1997-921295	19970421
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000510841	T2	20000822	JP 1997-540877	19970421
PRIORITY APPLN. INFO.:			US 1996-645894	A 19960514
			WO 1997-US6618	W 19970421

AB: Comps. and methods of administering nutritional supplements to the mouth  
 The compns. and methods of the present invention are based  
 on the encapsulation of the active ingredients that are encapsulated in lipid vesicles for  
 administration by aerosol or liq. droplet spray. A liposomal melatonin  
 is composed of lecithin 2.00, cholesterol 0.2, tocopherol acetate 0.4,  
 melatonin.HCl 0.05, glycerin 7.50, Et alc. 1.00, sodium  
 borate 20 1.00, flavor 1.00, citric acid 0.15, natural  
 flavor ext. 0.05, and water q.s. 100%. The encapsulated  
 melatonin is provided and increase of approx. 25% bioavailability  
 when administered orally as solid tablets.

IC ICM  
 ICS A61K009-12  
 CC 63-6 (Pharmaceuticals)  
 IT **Cardiolipins**  
 Ceramides  
**Lecithins**  
 Phosphatidylcholines, biological studies  
 Phosphatidylethanolamines, biological studies  
 Phosphatidylserines

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (delivery of biol. active material in liposomal formulation for  
 administration into mouth)

IT 57-55-6, 1,2-Propanediol, biological studies 57-88-5,  
 Cholest-5-en-3-ol (3.β.-), biological studies 58-95-7 64-17-5  
 , Ethanol, biological studies 73-31-4 303-98-0 25265-75-2,  
 Butanediol 27882-76-4 29031-19-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (delivery of biol. active material in liposomal formulation for  
 administration into mouth)

L93 ANSWER 21 OF 49 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 96182163 EMBASE

DOCUMENT NUMBER: 1996182163

TITLE: Antiphosphatidylserine antibodies in human immunodeficiency virus-1+ patients correlate with evidence of T-cell apoptosis and mediate antibody-dependent cellular cytotoxicity.

AUTHOR: Silvestris F.; Frassanito M.A.; Cafforio P.; Potenza D.; Di Loreto M.; Tucci M.; Grizzuti M.A.; Nico B.; Dammacco F.

CORPORATE SOURCE: Section of Internal Medicine, DIMO, P.zza Giulio Cesare, 11, 70124 Bari, Italy

SOURCE: Blood, (1996) 87/12 (5185-5195).

ISSN: 0006-4971 CODEN: BLOOAW

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 004 Microbiology

026 Immunology, Serology and Transplantation

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Serum reactivities to a panel of phospholipid antigens, including cardiolipin (CL), phosphatidylserine (PS), sphingomyelin, phosphatidylcholine, and phosphatidylethanolamine, were measured by enzyme-linked immunosorbent assay in 196 human immunodeficiency virus-1+ (HIV-1+) patients with CDC II to IVC clinical disease. Significant levels of IgG to CL, PS, or both were observed in 23 patients lacking evidence of thrombophilic events or any peculiar clinical feature of HIV-1 infection. Fluorescence-activated cell sorting analyses showed that in vitro apoptosis of T cells was increased in patients with high serum anti-PS IgG, whereas the overexpression of Fas/Apo-1 marker was detected in all patients regardless of their antiphospholipid reactivities. Macrophages from patients with significant titers of anti-PS IgG antibodies were not activated by the presence of apoptotic CEM lymphoblasts or by purified anti-PS IgG from the same patients. By contrast, these antibodies greatly improved the effector functions of autologous macrophages in antibody-dependent cellular cytotoxicity (ADCC) assays using <sup>51</sup>Cr-labeled CEM cells, whereas polyclonal IgG were unable to induce an equivalent cytotoxicity in all instances. An increasing effect on ADCC was also observed in tests using macrophages from healthy controls to CEM coated with anti-PS IgG. These results support a potential correlation of anti-PS specificity with T-cell apoptosis in HIV-1 infection. Because PS is exteriorized by apoptotic lymphocytes, its persistence may stimulate antibodies which cooperate with macrophages in the clearance of dead cells by an enhanced ADCC mechanism. This interpretation could explain the absence of thrombophilia in HIV-1+ patients with serum elevations of antiphospholipid reactivities.

CT Medical Descriptors:

\*apoptosis  
 \*human immunodeficiency virus infection  
 \*t lymphocyte  
 antibody dependent cellular cytotoxicity  
 article  
 controlled study  
 enzyme linked immunosorbent assay  
 flow cytometry  
 human  
 human cell  
 human immunodeficiency virus 1  
 macrophage  
 major clinical study  
 polyacrylamide gel electrophoresis  
 priority journal  
 diagnosis  
 Drug Descriptors:

\*immunoglobulin g antibody: EC, endogenous compound  
 \*phosphatidylserine: EC, endogenous compound

antigen  
 cardiolipin  
 cd3 antigen: EC, endogenous compound  
 cd4 antigen: EC, endogenous compound  
 cd8 antigen: EC, endogenous compound  
 chromium 51  
 dna: EC, endogenous compound  
 immunoglobulin g: EC, endogenous compound

phosphatidylcholine  
 phosphatidylethanolamine  
 phospholipid antibody: EC, endogenous compound  
 sphingomyelin

RN (chromium 51) 14392-02-0; (dna) 9007-49-2; (immunoglobulin g) 97794-27-9;  
 (phosphatidylcholine) 55128-59-1, 8002-43-5; (phosphatidylethanolamine)  
 1405-71-6; (sphingomyelin) 85187-10-6

L93 ANSWER 22 OF 49 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:528646 HCPLUS  
 DOCUMENT NUMBER: 122:274071

TITLE: Bioadhesive emulsions for enhanced drug delivery

INVENTOR(S): Friedman, Doron; Schwarz, Joseph; Amselem, Shimon

PATENT ASSIGNEE(S): Pharmos Corp., USA

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9505163	A1	19950223	WO 1994-US8803	19940805
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KR, NZ, PL, RU, SD, SI, SK, VN				
			BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	
19980428			US 1993-106262	19930813

AU 9474511	A1 19950314	AU 1994-74511	19940805
AU 692460	B2 19980611		
EP 714289	A1 19960605	EP 1994-924125	19940805
R: AT, BE, CH, DE, FR, GB, IE, IT, LI, LU			
IL 110588	A1 20000601	IL 1994-110588	19940808
US 5993846	A 19991130	US 1998-63660	19980421
PRIORITY APPLN. INFO.:		US 1993-106262	A 19930813
		WO 1994-US8803	W 19940805

AB Novel compns. are provided for administering drugs. to mucosal surface using bioadhesive emulsions of the "lipid-water" type contg. suitable drugs. Thus, a soln. of Carbopol-940 0.250 g and glycerol 11.2 g in 420 mL water was mixed with an oil phase consisting of pilocarpine 10.5, medium-chain triglycerides 21.2, Lipoïd E-75 3.75, and Miranol MHT 7.8 g. The mixt. was further mixed with 50 mg thiomersal and 1.0 g chlorobutanol in 50 mL water.

IC ICM A61K009-107

CC 63-6 (Pharmaceuticals)

IT Amino acids, biological studies

**Cardiolipins**

Estrogens

Glycerides, biological studies

Glycosaminoglycans, biological studies

Hormones

Lysophosphatidylcholines

Paraffin oils

Phosphatidic acids

Phosphatidylcholines, biological studies

Phosphatidylethanolamines

Phosphatidylglycerols

Phosphatidylinositols

Phosphatidylserines

Phospholipids, biological studies

Polymers, biological studies

Prostaglandins

Siloxanes and Silicones, biological studies

Vitamins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(bioadhesive emulsions for enhanced drug delivery)

IT **Lecithins**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(egg yolk, bioadhesive emulsions for enhanced drug delivery)

IT **Alcohols, biological studies**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(fatty, bioadhesive emulsions for enhanced drug delivery)

IT **Alcohols, biological studies**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(fatty, ethoxylated, bioadhesive emulsions for enhanced drug delivery)

IT 52-53-9, Verapamil 53-86-1, Indomethacin 54-71-7, Pilocarpine

hydrochloride 57-88-5, Cholesterol, biological studies

79-41-4D, Methacrylic acid, derivs., polymers 92-13-7, Pilocarpine

151-21-3, Sodium dodecyl sulfate, biological studies 9000-36-6, Karaya

gum 9000-65-1, Tragacanth gum 9000-69-5, Pectin 9003-01-4,

Poly(acrylic acid) 9003-39-8, PVP 9004-32-4 9004-54-0, Dextran T-70,

biological studies 9004-61-9, Hyaluronic acid 9004-99-3, Simulsol M53

9005-32-7, Alginic acid 9005-38-3, Sodium alginate 9005-49-6, Heparin,

biological studies 9005-65-6, Tween 80 9011-16-9, Maleic

anhydride-methyl vinyl ether copolymer 9012-76-4, Chitosan 9041-08-1,

Fragmin 15307-86-5, Diclofenac 25301-02-4, Tyloxapol 25322-68-3D, PEG, fatty esters or alkyl Ph ethers 71463-34-8, Miranol MHT 76050-42-5, Carbopol 940

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(bioadhesive emulsions for enhanced drug delivery)

L93 ANSWER 23 OF 49 HCAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1994:517729 HCAPLUS  
DOCUMENT NUMBER: 121:117729  
TITLE: Lipid-containing formulation and method for its preparation  
INVENTOR(S): New, Roger Randal Charles  
PATENT ASSIGNEE(S): Cortecs Ltd., UK  
SOURCE: PCT Int. Appl., 22 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9412154	A1	19940609	WO 1993-GB2393	19931122
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9455314	A1	19940622	AU 1994-55314	19931122
PRIORITY APPLN. INFO.:			GB 1992-24502	19921123
			WO 1993-GB2393	19931122

AB A method for prep. a pharmaceutical formulation of an active substance which is insol. in conventional solvents, comprises co-dissolving the active substance and an amphipathic lipid in an org. acid or acid anhydride and then removing or neutralizing the acid or acid anhydride. The resulting formulations may be liposomal or alternatively may take the form of lipid suspensions in aq. soln. or lipid-water gels. Active substances such as albendazole, which are sparingly sol. in conventional solvents, are particularly suited to formulation by the method of the

27

(cals)  
ference(s): 5, 62

Carotenoids, biological studies  
ological study)  
es contg., manuf. of)

IT ~~Car.~~ ~~ns~~  
~~Lecith.~~ ~~ns~~  
Phosphatidic acids  
Phosphatidylcholines, biological studies  
Phosphatidylglycerols  
Phosphatidylinositols  
Phosphatidylserines  
Phospholipids, biological studies  
Sphingomyelins

RL: BIOL (Biological study)  
(pharmaceutical liposomes manuf. with)

L93 ANSWER 24 OF 49 MEDLINE  
 ACCESSION NUMBER: 94355516 MEDLINE  
 DOCUMENT NUMBER: 94355516 PubMed ID: 8075274  
 TITLE: Retrobulbar neuritis complicating acute Epstein-Barr virus infection.  
 AUTHOR: Anderson M D; Kennedy C A; Lewis A W; Christensen G R  
 CORPORATE SOURCE: Department of Internal Medicine (Infectious Diseases), Naval Medical Center, San Diego, California.  
 SOURCE: CLINICAL INFECTIOUS DISEASES, (1994 May) 18 (5) 799-801.  
 Ref: 16  
 Journal code: 9203213. ISSN: 1058-4838.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW OF REPORTED CASES)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199410  
 ENTRY DATE: Entered STN: 19941013  
 Last Updated on STN: 19941013  
 Entered Medline: 19941003  
 AB A 19-year-old man presented with retrobulbar neuritis and was initially suspected to have neurosyphilis because of a positive microhemagglutination assay for Treponema pallidum (MHA-TP). However, a Venereal Disease Research Laboratory assay was negative, and the patient was subsequently diagnosed with infection due to Epstein-Barr virus (EBV) by heterophile antibody assay and serology for EBV. A biological false-positive MHA-TP has been reported in association with EBV infection. Physicians need to be aware that both retrobulbar neuritis and a biological false-positive MHA-TP can be seen in association with EBV infection.  
 CT Check Tags: Case Report; Human; Male; Support, U.S. Gov't, Non-P.H.S.  
 Adult  
 \*Antibodies, Heterophile: BL, blood  
 \*Antibodies, Viral: BL, blood  
 Antigens, Viral: IM, immunology  
 Cardiolipins: BL, blood  
 Cholesterol: BL, blood  
 Diagnosis, Differential  
 False Positive Reactions  
 \*Herpesvirus 4, Human  
 Herpesvirus 4, Human: IM, immunology  
 \*Infectious Mononucleosis: CO, comp.  
 Infectious Mononucleosis: DI, diag  
 Optic Neuritis: DI, diagnosis  
 \*Optic Neuritis: ET, etiology  
 Phosphatidylcholines: BL, blood  
 Syphilis: DI, diagnosis  
 Syphilis Serodiagnosis  
 RN 57-88-5 (Cholesterol)  
 CN 0 (Antibodies, Heterophile); 0 (Antibodies, Viral); 0 (Antigens, Viral); 0 (Cardiolipins); 0 (Epstein-Barr viral capsid antigen); 0 (Phosphatidylcholines); 0 (VDRL antigen)

L93 ANSWER 25 OF 49 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 3  
 ACCESSION NUMBER: 1994:161621 HCAPLUS  
 DOCUMENT NUMBER: 120:161621  
 TITLE: Immunoassay with solid phase-immobilized lipid antigen and magnetic particle-conjugated anti-human IgG or IgM antibody  
 INVENTOR(S): Tamaai, Toyohiro  
 PATENT ASSIGNEE(S): Olympus Optical Co, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05312808	A2	19931126	JP 1992-117674	19920511
PRIORITY APPLN. INFO.:			JP 1992-117674	19920511
AB Human antibodies are detd. by an immunoassay using solid phase-immobilized lipid antigens and magnetic particle-conjugated anti-human IgG or IgM antibodies. Thus, for syphilis diagnosis or anti-Treponema pallidum antibody detection in patients, a mixt. of cardiolipin, lecithin and cholesterol was immobilized on a microtiter plate, contacted with sample serum, treated with anti-human IgG-sensitized magnetic particles, and examd. for the pattern of the magnetic particle aggregation.				
IC	ICM G01N033-543			
	ICS G01N033-553			
ICA	G01N033-571			
CC	15-1 (Immunochemistry)			
IT	<b>Antigens</b>			
	RL: BIOL (Biological stu (lipid, solid phase-anti-human IgG or IgM blood)			articles sensitized with human antibodies in
IT	<b>Lecithins</b>			
	RL: BIOL (Biological stu (solid phase-immobilized cardiolipin and cholesterol and, anti-human IgG or IgM-sensitized magnetic particles and, for immunoassay of human antibodies)			
IT	<b>Cardiolipins</b>			
	RL: BIOL (Biological study) (solid phase-immobilized cholesterol and lecithin and, anti-human IgG or IgM-sensitized magnetic particles and, for immunoassay of human antibodies)			

L93 ANSWER 26 OF 49 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
 ACCESSION NUMBER: 93262841 EMBASE  
 DOCUMENT NUMBER: 1993262841  
 TITLE: Letter to the editor: <<Titre>> is not an internationally recognized quantity [1].  
 AUTHOR: Juan-Pereira L.; Fuentes-Arderiu X.  
 CORPORATE SOURCE: Servei d'Analisis Cliniques, Hospital Sant JoaD de Deu, E-08760 Martorell, Barcelona, Spain  
 SOURCE: European Journal of Clinical Chemistry and Clinical Biochemistry, (1993) 31/8 (541).  
 ISSN: 0939-4974 CODEN: EJCBE0

COUNTRY: Germany  
 DOCUMENT TYPE: Journal; Letter  
 FILE SEGMENT: 029 Clinical Biochemistry  
 LANGUAGE: English

CT Medical Descriptors:  
 \*quantitative assay  
 antigen antibody reaction  
 clinical laboratory  
 concentration  
 data analysis  
 dilution  
 erythrocyte  
 hemolysis  
 immunology  
 letter  
 priority journal  
**syphilis: DI, diagnosis**  
**syphilis: ET, etiology**

Drug Descriptors:

antibody  
 antigen  
**cardiolipin**  
 cardiolipin antibody  
 charcoal  
 cholesterol  
 latex  
**phosphatidylcholine**

RN reagent  
 (charcoal) 16291-96-6; (cholesterol) 57-88-5; (phosphatidylcholine)  
 55128-59-1, 8002-43-5

L93 ANSWER 27 OF 49 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 92334364 EMBASE  
 DOCUMENT NUMBER: 1992334364  
 TITLE: Obstetrical implications of antiphospholipid antibodies.  
 AUTHOR: Triplett D.A.  
 CORPORATE SOURCE: Department of Hematology, Ball Memorial Hospital, 2401  
 University Avenue, Muncie, IN 47303, United States  
 SOURCE: Bailliere's Clinical Obstetrics and Gynaecology, (1992) 6/3  
 (507-518).  
 ISSN: 0950-3552 CODEN: BCOGEH

COUNTRY: United Kingdom  
 DOCUMENT TYPE: Journal; General Review  
 FILE SEGMENT: 010 Obstetrics and Gynecology  
 026 Immunology, Serology and Transplantation

LANGUAGE: English

CT Medical Descriptors:

**\*infertility: DI, diagnosis**  
**\*infertility: ET, etiology**  
**\*systemic lupus erythematosus**  
 clinical article  
**endometriosis: DI, diagnosis**  
 endometriosis: ET, etiology  
 female  
 human  
**preeclampsia: DI, diagnosis**  
**preeclampsia: ET, etiology**

prothrombin time  
review

**syphilis**

Drug Descriptors:

\*autoantibody

\*lupus anticoagulant

**\*phosphatidylcholine**

\*phospholipid

**cardiolipin**

cholesterol

prostacyclin

protein kinase c: EC, endogenous compound

RN (phosphatidylcholine) 55128-59-1, 8002-43-5; (cholesterol) 57-88-5;  
(prostacyclin) 35121-78-9, 61849-14-7; (protein kinase c) 141436-78-4

L93 ANSWER 28 OF 49 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1991:499296 HCPLUS

DOCUMENT NUMBER: 115:99296

TITLE: Preparation of lipidic microparticles of  
water-insoluble pharmaceuticals

INVENTOR(S): Leclef, Brigitte; Cerfontaine, Patrick; Nicolas, Jean  
Marie; Wantier, Henri; Trouet, Andre

PATENT ASSIGNEE(S): Medgenix Group S. A., Belg.

SOURCE: Eur. Pat. Appl., 32 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 418153	A1	19910320	EP 1990-402509	19900912
EP 418153	B1	19930825		
EP 418153	B2	19960327		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2651680	A1	19910315	FR 1989-12038	19890914
FR 2651680	B1	19911227		
AT 93385	E	19930915	AT 1990-402509	19900912
ES 2060107	T3	19941116	ES 1990-402509	19900912
CA 2025298	AA	19910315	CA 1990-2025298	19900913
JP 03169808	A2	19910723	JP 1990-245991	19900914
JP 2831455	B2	19981202		
US 5100591	A	19920331	US 1990-582053	19900914
PRIORITY APPLN. INFO.:			FR 1989-12038	19890914
			EP 1990-402509	19900912

AB A process for prepn. of lipid microparticles of a water-insol. substance which is stable in an aq. suspension comprises (1) dissolving the substance and a phospholipid in an org. solvent, (2) mixing the org. solvent with an aq. soln. so that a ppt. is formed, (3) evapg. the org. solvent to obtain microparticles of the substance in microsuspension form. Amphotericin B (I) and L-.alpha.-phosphatidylcholine were dissolved in a mixt. of MeOH:CHCl<sub>3</sub> (1:1) and to this soln. was added a soln. of 0.9% NaCl. The org. solvent was evapd. to obtain a suspension of I microparticles.

IC ICM A61K009-16  
ICS A61K009-127

CC 63-6 (Pharmaceuticals)  
 IT **Cardiolipins**  
 Phosphatidylcholines, biological studies  
 Phosphatidylethanolamines  
 Phosphatidylglycerols  
 Phosphatidylinositols  
 Phosphatidylserines  
 Phospholipids, biological studies  
 RL: BIOL (Biological study)  
 (in prepn. of lipid microparticles of water-insol. substances)  
 IT **Lecithins**  
 RL: PREP (Preparation)  
 (egg yolk, in prepn. of lipid microparticles of water-insol. substances)  
 IT **Lecithins**  
 RL: PREP (Preparation)  
 (hydrogenated, in prepn. of lipid microparticles of water-insol. substances)  
 IT **Lecithins**  
 RL: PREP (Preparation)  
 (soya, in prepn. of lipid microparticles of water-insol. substances)  
 IT 57-55-6, Propylene glycol, biological studies 57-88-5D,  
 Cholesterol, esters 63-42-3, Lactose 64-17-5, Ethanol,  
 biological studies 67-56-1, Methanol, biological studies 68-12-2,  
 Dimethylformamide, biological studies 127-19-5, Dimethylacetamide  
 2644-64-6, Dipalmitoylphosphatidylcholine 3036-82-6,  
 Dipalmitoylphosphatidylserine 4539-70-2, Distearylphosphatidylcholine  
 7726-03-6 13699-48-4, Dimyristoylphosphatidylcholine 14265-44-2,  
 Phosphate, biological studies 26264-14-2, Propane diol 42241-11-2  
 61361-72-6, Dimyristoylphosphatidylglycerol 111883-34-2,  
 Distearylphosphatidylglycerol  
 RL: BIOL (Biological study)  
 (in prepn. of lipid microparticles of water-insol. substances)

L93 ANSWER 29 OF 49 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
 ACCESSION NUMBER: 92032643 EMBASE  
 DOCUMENT NUMBER: 1992032643  
 TITLE: Specific binding of antibodies to platelet-activating factor (PAF) as demonstrated by thin-layer chromatography/immunostaining.  
 AUTHOR: Karasawa K.; Satoh N.; Hongo T.; Nakagawa Y.; Setaka M.; Nojima S.  
 CORPORATE SOURCE: Department of Membrane Biology, Fac. of Pharmaceutical Science, Teikyo University, Sagamiko, Kanagawa 199-01, Japan  
 SOURCE: Lipids, (1991) 26/12 (1122-1125).  
 ISSN: 0024-4201 CODEN: LPDSAP  
 COUNTRY: United States  
 DOCUMENT TYPE: Journal; Conference Article  
 FILE SEGMENT: 026 Immunology, Serology and Transplantation  
 029 Clinical Biochemistry  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English  
 AB The specificity of rabbit antibodies produced by injection of 1-O-(15'-carboxypentadecyl)-2-N,N-dimethylcarbamoyl-sn-glycero-3-phosphocholine bovine serum albumin (BSA) conjugates was examined by a thin-layer chromatography (TLC)/immunostaining method. Phosphatidylcholine (PC), lysophosphatidylcholine (lysoPC), lyso platelet-activating factor

(lysoPAF), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylserine (PS), sphingomyelin (SM), phosphatidylinositol (PI), phosphatidic acid (PA) and cardiolipin (CL) were not immunostained. Among several synthetic PAF- related compounds, the antibodies only bound to PAF agonists which have the activity to induce washed rabbit platelet aggregation. The results suggest that the binding sites of the antibodies on the PAF molecule are the acetyl group at the sn-2 position and the choline moiety at the sn-3 position of glycerol, both of which are essential for exerting the biological function of PAF and for binding to the PAF receptors located on cellular membranes.

CT

## Medical Descriptors:

- \*antibody specificity
- \*antigen binding
- \*immunohistochemistry
- \*thin layer chromatography
- \*thrombocyte activation
- animal cell
- antibody combining site
- conference paper
- cross reaction
- immunoreactivity
- nonhuman
- priority journal
- rabbit
- stereospecificity
- structure activity relation
- technique
- thrombocyte aggregation

## Drug Descriptors:

- thrombocyte activating factor receptor
- \*glycerophospholipid
- \*thrombocyte activating factor: EC, endogenous compound
- \*thrombocyte activating factor derivative

## antigen

- bovine serum albumin
- cardiolipin**
- dipalmitoylphosphatidylcholine
- lysophosphatidylcholine
- phosphatidic acid
- phosphatidylcholine**
- phosphatidylethanolamine
- phosphatidylglycerol
- phosphatidylinositol
- phosphatidylserine
- sphingomyelin

RN (thrombocyte activating factor) 64176-80-3, 65154-06-5;  
 (dipalmitoylphosphatidylcholine) 2644-64-6; (lysophosphatidylcholine) 93794-93-5; (phosphatidylcholine) 55128-59-1, 8002-43-5;  
 (phosphatidylethanolamine) 1405-71-6; (sphingomyelin) 85187-10-6

L93 ANSWER 30 OF 49 MEDLINE

ACCESSION NUMBER: 91161196 MEDLINE

DOCUMENT NUMBER: 91161196 PubMed ID: 2074116

TITLE: Anti-phospholipid antibody profiles of different specificities in syphilis and systemic lupus erythematosus.

AUTHOR: Shieh M T; Pierce C; Bartholomew W; Kumar V

CORPORATE SOURCE: Department of Medical Technology, University at Buffalo,

SUNY 14214.  
 SOURCE: IMMUNOLOGICAL INVESTIGATIONS, (1990 Oct-Dec) 19 (5-6)  
 507-18.  
 Journal code: 8504629. ISSN: 0882-0139.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199104  
 ENTRY DATE: Entered STN: 19910505  
 Last Updated on STN: 19910505  
 Entered Medline: 19910416

AB Controversies exist as to the differences in the specificities of phospholipid antibodies in SLE and syphilis. We report an ELISA assay that could distinguish phospholipid antibodies associated with SLE and syphilis based on their differential reactions with phosphatidyl choline and VDRL antigens. Antibodies to phospholipid from patients with SLE reacted equally well when tested with these two antigens in the ELISA assay whereas phospholipid antibodies present in syphilis patients exhibited little or no binding to phosphatidyl choline. There were no differences in the binding of phospholipid antibodies to other phospholipids such as cardiolipin and phosphatidyl serine. In addition, there was no association of anti-phospholipid antibodies with the presence of either DNA or RPR antibodies suggesting their distinctness from each other.

CT Check Tags: Human  
 Antibodies, Antinuclear: IM, immunology  
 \*Antibody Specificity: IM, immunology  
 Antigens, Bacterial: IM, immunology  
 \*Autoantibodies: IM, immunology  
 Cardiolipins: IM, immunology  
 Enzyme-Linked Immunosorbent Assay  
 \*Lupus Erythematosus, Systemic: IM, immunology  
 Phosphatidylcholines: IM, immunology  
 Phosphatidylserines: IM, immunology  
 \*Phospholipids: IM, immunology  
 \*Syphilis: IM, immunology  
 Treponema pallidum: IM, immunology

CN 0 (Antibodies, Antinuclear); 0 (Antigens, Bacterial); 0 (Autoantibodies);  
 0 (Cardiolipins); 0 (Phosphatidylcholines); 0 (Phosphatidylserines); 0  
 (Phospholipids)

L93 ANSWER 31 OF 49 MEDLINE  
 ACCESSION NUMBER: 91248923 MEDLINE  
 DOCUMENT NUMBER: 91248923 PubMed ID: 2095259  
 TITLE: [Evaluation of an immunoenzyme technique for the diagnosis of syphilis].  
 Evaluacion de una tecnica inmunoenzimatica en el diagnostico de sifilis.  
 AUTHOR: Borobio M V; Ruiz J M; Perea E J  
 CORPORATE SOURCE: Departamento de Microbiologia, Facultad de Medicina,  
 Sevilla.  
 SOURCE: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, (1990  
 Oct) 8 (8) 486-9.  
 Journal code: 9104081. ISSN: 0213-005X.  
 PUB. COUNTRY: Spain  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: Spanish  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199107  
 ENTRY DATE: Entered STN: 19910728  
                   Last Updated on STN: 19910728  
                   Entered Medline: 19910711  
 AB A comparative study of an enzyme immunoassay (EIA Captia Syphilis Mercia), FTA-Abs and VDRL to detect anti-Treponema pallidum antibodies was carried out in overall 290 subjects: 113 had a diagnosis of syphilis (40 primary and 73 secondary) and 117 were controls (40 with nonsyphilitic ulcers, 52 with falsely positive VDRL and 85 healthy subjects). The overall correlations between EIA Captia and FTA and with VDRL were 92% and 72%, respectively. The sensitivity of the method was 82%, with 98% specificity.  
 CT Check Tags: Comparative Study; Human  
       \*Antibodies, Bacterial: AN, analysis  
           Cardiolipins: DU, diagnostic use  
           Cholesterol: DU, diagnostic use  
           Diagnosis, Differential  
           English Abstract  
           Evaluation Studies  
           \*Fluorescent Antibody Technique  
           \*Immunoenzyme Techniques  
           Phosphatidylcholines: DU, diagnostic use  
           Reagent Kits, Diagnostic  
           Sensitivity and Specificity  
           \*Syphilis Serodiagnosis  
           \*Treponema pallidum: IM, immunology  
 RN 57-88-5 (Cholesterol)  
 CN 0 (Antibodies, Bacterial); 0 (Cardiolipins); 0 (Phosphatidylcholines); 0 (Reagent Kits, Diagnostic); 0 (VDRL antigen)

L93 ANSWER 32 OF 49 MEDLINE  
 ACCESSION NUMBER: 91242673 MEDLINE  
 DOCUMENT NUMBER: 91242673 PubMed ID: 2094408  
 TITLE: Syphilis serology and human immunodeficiency virus positivity in Chandigarh.  
 AUTHOR: Kumar B; Rajagopalan M; Sehgal S; Sharma M; Malhotra S  
 CORPORATE SOURCE: Department of Dermatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.  
 SOURCE: INTERNATIONAL JOURNAL OF STD AND AIDS, (1990 Nov) 1 (6) 438-9.  
           Journal code: 9007917. ISSN: 0956-4624.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals; AIDS  
 ENTRY MONTH: 199107  
 ENTRY DATE: Entered STN: 19910719  
                   Last Updated on STN: 19970203  
                   Entered Medline: 19910703  
 AB AIDS and other sexually transmitted diseases are interlinked. VDRL positivity may indicate that the individual has an increased risk of being HIV positive as the epidemiological risk factors for developing syphilis and AIDS are similar. We analysed 323 (5.8%) VDRL positive serum samples (out of 5592 screened) for HIV positivity. All were HIV negative. While syphilitic infection in India at present is not commonly associated with

CT HIV infection, experience in other countries indicates caution.  
 Check Tags: Female; Human; Male  
 Adolescent  
 Adult  
**Cardiolipins: BL, blood**  
 Child  
 Child, Preschool  
 Cholesterol: BL, blood  
**Enzyme-Linked Immunosorbent Assay**  
 HIV Seropositivity: BL, blood  
 HIV Seropositivity: CO, complications  
 \*HIV Seropositivity: EP, epidemiology  
 India: EP, epidemiology  
 Infant  
 Middle Age  
**Phosphatidylcholines: BL, blood**  
 Risk Factors  
**Syphilis: BL, blood**  
**\*Syphilis: CO, complications**  
 RN 57-88-5 (Cholesterol)  
 CN 0 (Cardiolipins); 0 (Phosphatidylcholines); 0 (VDRL antigen)

L93 ANSWER 33 OF 49 MEDLINE  
 ACCESSION NUMBER: 91354664 MEDLINE  
 DOCUMENT NUMBER: 91354664 PubMed ID: 2518811  
 TITLE: [Comparison of methods for the demonstration of Treponema-specific IgM].  
 Metodologie a confronto per la ricerca di IgM Treponema-specifiche.  
 AUTHOR: Panuccio A; Borroni G; Gelosa L  
 CORPORATE SOURCE: Istituto di Microbiologia dell'Universita di Milano.  
 SOURCE: BOLLETTINO DELL ISTITUTO SIEROTERAPICO MILANESE, (1989) 68 (2) 145-51.  
 Journal code: 17720040R. ISSN: 0021-2547.  
 PUB. COUNTRY: Italy  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: Italian  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199110  
 ENTRY DATE: Entered STN: 19911027  
 Last Updated on STN: 19911027  
 Entered Medline: 19911010

AB In this research 113 sera have been analysed with three methods for IgM treponema-specific determination: IgM-SPHA, IgM-EIA and 19S IgM FTA-ABS. Among these sera, 33 samples related to non-treated patients at different stages of infection, and 80 samples to treated patients. The results point out a light sensibility of the IgM-SPHA in primary lues. The IgM-EIA test has performed a good specificity, but displayed a sensibility lower to the 19S IgM FTA-ABS, which proved the best of tests. About the cases of treated lues at different stages, in 23 samples with VDRL negative has been found no positivity at three tests used, while in 49 samples with VDRL positive 8 are resulted positive at 19S IgM FTA-ABS.

CT Check Tags: Comparative Study; Human  
 \*Antibodies, Bacterial: BL, blood  
**Cardiolipins: DU, diagnostic use**  
 Cholesterol: DU, diagnostic use  
 English Abstract

**Enzyme-Linked Immunosorbent Assay****Immunodiffusion**

\*Immunoglobulin M: AN, analysis

**Phosphatidylcholines: DU, diagnostic use**

Predictive Value of Tests

Reagent Kits, Diagnostic

**\*Syphilis Serodiagnosis: MT, methods****Syphilis, Latent: DI, diagnosis****\*Treponema pallidum: IM, immunology**

RN 57-88-5 (Cholesterol)

CN 0 (Antibodies, Bacterial); 0 (Cardiolipins); 0 (Immunoglobulin M); 0 (Phosphatidylcholines); 0 (Reagent Kits, Diagnostic); 0 (VDRL antigen)

L93 ANSWER 34 OF 49 MEDLINE

ACCESSION NUMBER: 88089013 MEDLINE

DOCUMENT NUMBER: 88089013 PubMed ID: 3335805

TITLE: Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders.

AUTHOR: Harris E N; Gharavi A E; Wasley G D; Hughes G R

CORPORATE SOURCE: Lupus Research Laboratory, Rayne Institute, London, England.

SOURCE: JOURNAL OF INFECTIOUS DISEASES, (1988 Jan) 157 (1) 23-31.  
Journal code: 0413675. ISSN: 0022-1899.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 198802

ENTRY DATE: Entered STN: 19900305

Last Updated on STN: 19900305

Entered Medline: 19880203

AB We report a VDRL-enzyme-linked immunosorbent assay (ELISA) that enabled us to distinguish between the antibodies to cardiolipin from patients with autoimmune disorders and those from patients with syphilis. Additional studies using inhibition experiments with phospholipid liposomes, as well as ELISAs with a variety of phospholipid antigens, showed that antibodies to phospholipids from patients with syphilis bind cardiolipin (best when presented as the VDRL antigen) but exhibited little cross-reactivity with negatively charged phospholipids. On the other hand, antibodies to phospholipids from patients with autoimmune disorders exhibited little or no binding to the VDRL antigen but cross-reacted with both cardiolipin and negatively charged phospholipids. These findings may explain why antibodies to phospholipids only from patients with autoimmune disorders may have lupus anticoagulant activity and why they are associated with thrombosis, fetal loss, and thrombocytopenia.

CT Check Tags: Comparative Study; Human; Support, Non-U.S. Gov't

Antibodies: IM, immunology

\*Autoantibodies: IM, immunology

\*Autoimmune Diseases: IM, immunology

**\*Cardiolipins: IM, immunology**

Cholesterol: IM, immunology

Cross Reactions

**\*Enzyme-Linked Immunosorbent Assay**

Liposomes

**Phosphatidylcholines: IM, immunology**

Phospholipids: IM, immunology

\*Syphilis: IM, immunology

RN 57-88-5 (Cholesterol)  
 CN 0 (Antibodies); 0 (Autoantibodies); 0 (Cardiolipins); 0 (Liposomes); 0 (Phosphatidylcholines); 0 (Phospholipids); 0 (VDRL antigen)

L93 ANSWER 35 OF 49 MEDLINE DUPLICATE 4  
 ACCESSION NUMBER: 88008289 MEDLINE  
 DOCUMENT NUMBER: 88008289 PubMed ID: 3308951  
 TITLE: Enzyme-linked immunosorbent assay for detection of antibodies to the venereal disease research laboratory (VDRL) antigen in syphilis.  
 AUTHOR: Pedersen N S; Orum O; Mouritsen S  
 CORPORATE SOURCE: Department of Treponematoses, Statens Serum Institut, Copenhagen, Denmark.  
 SOURCE: JOURNAL OF CLINICAL MICROBIOLOGY, (1987 Sep) 25 (9) 1711-6.  
 Journal code: 7505564. ISSN: 0095-1137.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 198711  
 ENTRY DATE: Entered STN: 19900305  
 Last Updated on STN: 19900305  
 Entered Medline: 19871120

AB An enzyme-linked immunosorbent assay (ELISA) for detection of immunoglobulin G (IgG) and IgM to cardiolipin, lecithin, and cholesterol (VDRL [Venereal Disease Research Laboratory] ELISA) is described. The specificity of the VDRL ELISA for IgG and IgM was 99.6 and 99.5%, respectively, with sera from 1,008 persons without syphilis. For a group of patients with false-positive results in traditional nontreponemal tests and for patients with autoimmune diseases, the VDRL ELISA for IgG had a higher specificity than the VDRL ELISA for IgM. The sensitivity for IgG and IgM with 118 sera from patients with untreated syphilis was 96.6 and 94.9%, respectively, which was equivalent to the sensitivities of the traditional nontreponemal tests. The performance of the VDRL ELISA was compared with that of an ELISA that uses cardiolipin as the antigen (cardiolipin ELISA). The VDRL ELISA was significantly more sensitive (P less than or equal to 0.01) than the cardiolipin ELISA with 25 sera from syphilis patients but was less sensitive (P less than or equal to 0.01) with 53 sera from patients with autoimmune diseases. The antibody reactivity in the VDRL ELISA could not be absorbed out by lecithin and cholesterol, and the sera from patients with syphilis did not react in an ELISA that uses cholesterol and lecithin as the antigen. This indicates that cholesterol and lecithin, although not antigenic by themselves, may change the structural form of the epitope on cardiolipin so that it becomes more recognizable for antibodies in syphilis and less recognizable for antibodies in autoimmune diseases. The results of the VDRL ELISA were expressed in percentages of the absorbance value of a positive control. The VDRL ELISA gave, without titration of sera, quantitative results that correlated with the quantitative results of the traditional nontreponemal tests obtained by titration. The VDRL ELISA will be well suited for large-scale testing for syphilis and may replace other nontreponemal tests.

CT Check Tags: Comparative Study; Human  
 \*Antibodies, Bacterial: AN, analysis  
 \*Antigens, Bacterial: IM, immunology

Autoimmune Diseases: IM, immunology

**Cardiolipins: IM, immunology**

Cholesterol: IM, immunology

**\*Enzyme-Linked Immunosorbent Assay**

**False Positive Reactions**

Immunoglobulin G: AN, analysis

Immunoglobulin M: AN, analysis

Immunoglobulins: AN, analysis

**Phosphatidylcholines: IM, immunology**

Predictive Value of Tests

Rheumatoid Factor

**Syphilis: IM, immunology**

**\*Syphilis Serodiagnosis**

**\*Treponema pallidum: IM, immunology**

RN 57-88-5 (Cholesterol); 9009-79-4 (Rheumatoid Factor)

CN 0 (Antibodies, Bacterial); 0 (Antigens, Bacterial); 0 (Cardiolipins); 0 (Immunoglobulin G); 0 (Immunoglobulin M); 0 (Immunoglobulins); 0 (Phosphatidylcholines)

L93 ANSWER 36 OF 49 MEDLINE

ACCESSION NUMBER: 87128545 MEDLINE

DOCUMENT NUMBER: 87128545 PubMed ID: 3814360

TITLE: The cardiolipin antigen: chemistry and composition.

AUTHOR: Ngeh-Ngwainbi J; Kuan S S; Steinman F; Guilbault G G

SOURCE: BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, (1986 Dec) 8 (6) 553-63.

Journal code: 8609465. ISSN: 0885-4513.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198704

ENTRY DATE: Entered STN: 19900303

Last Updated on STN: 19900303

Entered Medline: 19870410

AB Cardiolipin, the primary lipid hapten in the antigen suspension used for the detection of antitreponemal antibodies in the sera of syphilitic patients, was successfully coupled to glucose oxidase, peroxidase, and some other enzymes using different crosslinking agents. These complexes were used to replace the pure uncomplexed cardiolipin for the preparation of the antigen suspension. When these suspensions were allowed to react with serum that contained anticardiolipin antibodies the activity of the enzyme was inhibited. In the absence of antibody, no enzyme inhibition was observed.

CT Check Tags: Human

\*Antibodies, Bacterial: AN, analysis

**\*Antigens: AN, analysis**

**\*Cardiolipins: AN, analysis**

Cholesterol: AN, analysis

Complement

Indicators and Reagents

Magnetic Resonance Spectroscopy

**Phosphatidylcholines: AN, analysis**

\*Syphilis: DI, diagnosis

**Syphilis: IM, immunology**

RN 57-88-5 (Cholesterol); 9007-36-7 (Complement)

CN 0 (Antibodies, Bacterial); 0 (Antigens); 0 (Cardiolipins); 0 (Indicators)

and Reagents); 0 (Phosphatidylcholines)

L93 ANSWER 37 OF 49 HCAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1983:434319 HCAPLUS  
 DOCUMENT NUMBER: 99:34319  
 TITLE: Metabolic factors and preference for ethanol  
 AUTHOR(S): Ostrovskii, Yu. M.; Sadovnik, M. N.; Satanovskaya, V. I.; Ostrovskii, S. Yu.; Selevich, M. I.; Buko, V. U.; Lelevich, V. I.; Lukashik, N. K.  
 CORPORATE SOURCE: Div. Metab. Regul., Byeloruss. Acad. Sci., Grodno, 230009, USSR  
 SOURCE: Pharmacology, Biochemistry and Behavior (1983), 18 (Suppl. 1), 531-5  
 CODEN: PBBHAU; ISSN: 0091-3057  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB ETOH [64-17-5] intoxication diminishes the metabolic differences between EtOH- and water-preferring rats in the levels of free amino acids (liver, brain, blood plasma), lipid fractions (liver), the activities of glucokinase [9001-36-9] (liver), and aldehyde dehydrogenase [9028-86-8] (brain), and the content of glucose 6-phosphate [56-73-5] and prostaglandins (liver). The action of EtOH is discussed as that directed to the partial elimination of biochem. individuality, thus simplifying the regulation of metab. in the living system. Thus, preferential EtOH consumption may be regarded as a biol. mode of self-correction.

CC 4-7 (Toxicology)  
 IT Cardiolipins  
 Cephalins  
 Glycerides, biological studies  
 Lecithins  
 Lysophosphatidylcholines  
 Sphingomyelins  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (of liver, ethanol effect on, ethanol preference in relation to)  
 IT 57-88-5, biological studies  
 RL: BIOL (Biological study)  
 (of blood plasma and liver and muscle, ethanol effect on, ethanol preference in relation to)  
 IT 64-17-5, biological studies  
 RL: BIOL (Biological study)  
 (preference for, metabolic factors in relation to)

L93 ANSWER 38 OF 49 DRUGU COPYRIGHT 2003 THOMSON DERWENT  
 ACCESSION NUMBER: 1983-36728 DRUGU M  
 TITLE: Construction of Lipid Diagnostic Preparations (Review).  
 AUTHOR: Krasnopol'skaya Y M; Golbets I I; Orlova G L; Sennikov G A; Shvets V I  
 LOCATION: Kharkov, Moscow, Russia  
 SOURCE: Khim. Farm. Zh. (17, No. 4, 401-10, 1983)  
 CODEN: KHFZAN ISSN: 0023-1134  
 AVAIL. OF DOC.: Institute for the Production of Bacterial Preparations, Kharkov, U.S.S.R.  
 LANGUAGE: Russian  
 DOCUMENT TYPE: Journal  
 FIELD AVAIL.: AB; LA; CT  
 FILE SEGMENT: Literature

AB Developments in the **diagnosis of syphilis** are reviewed.

L93 ANSWER 39 OF 49 HCAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1982:437437 HCAPLUS  
 DOCUMENT NUMBER: 97:37437  
 TITLE: Serologic test reagents for syphilis diagnosis  
 PATENT ASSIGNEE(S): Eiken Chemical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 57048659	A2	19820320	JP 1980-124171	19800908
			JP 1980-124171	19800908

## PRIORITY APPLN. INFO.:

AB A lipid antigen, prep'd. from bovine cardiolipin plus lecithin and cholesterol as a sensitizer, is treated with Sudan Black and immobilized on kaolin particles to produce an immunol. test reagent for syphilis diagnosis by an agglutination reaction. The reagent has high sensitivity and forms large aggregates which can be obsd. visually. Thus, 100 mL of a mixt. (contg. cardiolipin 66.15, lecithin 486.0, cholesterol 200, Sudan Black 165 mg, and EtOH to 100 mL) and 80 mL of a buffer (contg. Na<sub>2</sub>HPO<sub>4</sub> 2.82, KH<sub>2</sub>PO<sub>4</sub> 2.72, NaCl 10 g, and water to 1 L) were mixed. To the mixt. was added 820 mL of a suspension contg. kaolin 1.5, Na<sub>2</sub>HPO<sub>4</sub> 2.82, KH<sub>2</sub>PO<sub>4</sub> 2.72, NaCl 10 g, and water to 1 L. The mixt. was heated at 100.degree. for 10 min, rapidly cooled, centrifuged, and the ppt. was suspended in 750 mL of the buffer. To the suspension were added 0.25M di-Na EDTA 75 mL and water to 1.5 L to obtain a reagent. One drop of the reagent was added to 50 .mu.L of a serum sample and mixed on a glass slide. Wassermann antibody-pos. serum formed an aggregate on the glass slide.

IC G01N033-54

CC 15-1 (Immunochemistry)

Section cross-reference(s): 14

IT **Cardiolipins**

RL: BIOL (Biological study)

(antibodies to, detection of, in human blood serum in syphilis diagnosis)

IT **Antigens**

RL: PREP (Preparation)

(cardiolipin-contg., prep'n. of, for syphilis diagnosis in humans)

IT **Lecithins**

RL: BIOL (Biological study)

(reagent contg., for syphilis diagnosis in humans)

L93 ANSWER 40 OF 49 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1981:598788 HCAPLUS

DOCUMENT NUMBER: 95:198788

TITLE: Effect of dietary ethanol and cholesterol on phospholipid composition of hepatic mitochondria and microsomes from the monkey, *Macaca nemestrina*

AUTHOR(S): Cunningham, Carol C.; Sinthusek, Govit; Spach, Priscilla I.; Leathers, Charles

CORPORATE SOURCE: Bowman Gray Sch. Med., Wake Forest Univ.,

Winston-Salem, NC, 27103, USA  
 SOURCE: Alcoholism: Clinical and Experimental Research  
 (1981), 5(3), 417-26  
 CODEN: ACRSDM; ISSN: 0145-6008

DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Monkeys were divided into 4 groups, and each group was fed a particular diet. The variables in the diets were as follows: diet A, 0.3 mg cholesterol (I) [57-88-5]/kcal nutrient; diet B, 1.0 mg I/kcal nutrient; diet C, 0.3 mg I/kcal nutrient, EtOH [64-17-5] (36% of calories); diet D, 1.0 mg I/kcal nutrient, EtOH (36% of calories). Monkeys on the diets contg. EtOH developed fatty liver. Mitochondria and microsomes isolated from these livers demonstrated EtOH-elicited alterations in metabolic functions. Accompanying these changes in metabolic activities were alterations in organelle phospholipids that were influenced by both dietary EtOH and I. The changes attributed to EtOH were: phosphatidylethanolamine was decreased in microsomes and increased in mitochondria; the sphingomyelin content in microsomes was increased significantly. The levels of stearic acid [57-11-4] and arachidonic acid [506-32-1] were elevated and palmitic acid [57-10-3] and oleic acid [112-80-1] decreased, in phospholipids from both mitochondria and microsomes. I influenced the fatty acid compn. of several phospholipids, usually in a direction opposite to those alterations attributed to EtOH. I feeding increased levels of palmitic and oleic acid and decreased amts. of stearic, linoleic, and arachidonic acid in several phospholipids. The significant EtOH- and I-elicited alterations obsd. suggest the possibility that the changes in metabolic functions in mitochondria and microsomes are controlled, at least in part, by alterations in the phospholipid compns. of these organelles.

CC 4-13 (Toxicology)

IT **Lecithins, biological studies**

RL: BIOL (Biological study)  
 (diacyl and monoacyl, of liver microsome and mitochondria, of monkey, cholesterol and ethanol effect on)

IT **Cardiolipins**

Fatty acids, biological studies

Phospholipids

Sphingomyelins

RL: BIOL (Biological study)  
 (of liver microsome and mitochondria, of monkey, dietary cholesterol and ethanol effect on)

IT **64-17-5, biological studies**

RL: BIOL (Biological study)  
 (liver microsome and mitochondria phospholipid compn. in response to cholesterol and, in monkey)

IT **57-88-5, biological studies**

RL: BIOL (Biological study)  
 (liver microsome and mitochondria phospholipid compn. response to ethanol and, in monkey)

L93 ANSWER 41 OF 49 MEDLINE

ACCESSION NUMBER: 81264624 MEDLINE

DOCUMENT NUMBER: 81264624 PubMed ID: 7263853

TITLE: Relationship of phospholipid chemistry to serological reactivity in the Venereal Disease Research Laboratory slide test antigen.

AUTHOR: Reeves M W; McGrew B E; McLaurin B; Pine L

SOURCE: JOURNAL OF CLINICAL MICROBIOLOGY, (1981 Jul) 14 (1) 48-54.  
 Journal code: 7505564. ISSN: 0095-1137.

PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 198110  
 ENTRY DATE: Entered STN: 19900316  
 Last Updated on STN: 19900316  
 Entered Medline: 19811014

AB A total of 13 egg lecithins, 12 beef heart lecithins, and 15 beef heart cardiolipins were assayed for the ability to function in the Venereal Disease Research Laboratory microflocculation test, as well as for purity, fatty acid composition, free amines, metals, and products of oxidation. We found that the presence of peroxides and oxidation-related ultraviolet-absorbing chromophores showed a close inverse relationship to acceptable serological activity. The degree of purity of the lipids had only a slight influence on serological activity, whereas fatty acid composition, saturation, and configuration had none at all. We did not detect contaminating iron, copper, cobalt, nickel, or free amines in these lipids. We discuss the implications of our findings for improving the chemical standards for these lipids.

## CT \*Antigens

Cardiolipins: AN, analysis

Cardiolipins: IM, immunology

Fatty Acids, Unsaturated: AN, analysis

\*Flocculation Tests

Peroxides: AN, analysis

Phosphatidylcholines: AN, analysis

Phosphatidylcholines: IM, immunology

\*Phospholipids: IM, immunology

\*Syphilis Serodiagnosis: MT, methods

CN 0 (Antigens); 0 (Cardiolipins); 0 (Fatty Acids, Unsaturated); 0 (Peroxides); 0 (Phosphatidylcholines); 0 (Phospholipids)

L93 ANSWER 42 OF 49 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1981:154614 HCPLUS

DOCUMENT NUMBER: 94:154614

TITLE: Lipid immunogenicity

AUTHOR(S): Krasnopol'skii, Yu. M.; Orlova, G. L.; Gol'bets, I. I.; Sennikov, G. A.; Vasilenko, I. A.; Shvets, V. I.

CORPORATE SOURCE: USSR

SOURCE: Khimiya i Tekhnologiya Organicheskikh Proizvodstv (1979), 9(2), 80-5

CODEN: KTOPDN

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB The immunogenicity of liposomes, which have a wide variety of applications in medicine such as drug carriers and diagnostic agents, was investigated. The lipids tested, cardiolipin, phosphatidylcholine, and cholesterol [57-88-5], are used as antigenic liposomes in the diagnosis of syphilis. Immune reactions were obsd. in rabbits to one of the components of the liposomes, cardiolipin. The other 2 components themselves did not induce antigen formation, whereas they enhanced the immune reaction to cardiolipin when administered in combination with the latter. The highest antibody titers were obsd. following administration of the 3 components along with bovine serum albumin. The physicochem. properties of the

antigens formed were similar to those previously obsd. for syphilitic serum antigens.

CC 15-1 (Immunochemistry)

IT **Cardiolipins**

RL: BIOL (Biological study)  
(as syphilis artificial antigen, of liposome, in syphilis diagnosis)

IT **Lecithins, biological studies**

RL: BIOL (Biological study)  
(liposome contg. cardiolipin and cholesterol and, as syphilis artificial antigen in syphilis diagnosis)

IT **Antigens**

RL: BIOL (Biological study)  
(syphilis-related, artificial, liposome contg. cardiolipin and cholesterol and lecithin as, in syphilis diagnosis)

L93 ANSWER 43 OF 49 WPIX (C) 2003 THOMSON DERWENT

ACCESSION NUMBER: 1979-59379B [32] WPIX

TITLE: **Cardiolipin antigen for syphilis diagnosis - contg. cardiolipin, lecithin, cholesterol, butyl-oxy-toluene and absolute ethanol for accuracy.**

DERWENT CLASS: B05

INVENTOR(S): GOLBETS, I I; SENNIKOV, G A; SHVETS, V I

PATENT ASSIGNEE(S): (BACT-R) BACTERIAL PREPN WKS; (MOFJ) MOSC FINE CHEM MECH

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
SU 629927	A	19781005	(197932)*		

PRIORITY APPLN. INFO: SU 1977-2502377 19770630

AB SU 629927 A UPAB: 19930901

**Cardiolipin antigen for diagnosis of syphilis**  
comprises (in wt.-%): **cardiolipin** (15-17)x10-3; **lecithin** (58-62)x10-3; **cholesterol** (2.9-3-1)x10-1 butyloxy-toluene (19.5-20.5)x10-3 and absolute **ethanol** the rest.

The addn. of butyloxy-toluene improves the accuracy of diagnosis.

L93 ANSWER 44 OF 49 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1977:500391 HCAPLUS

DOCUMENT NUMBER: 87:100391

TITLE: Immunoresponsive membrane. I. Membrane potential change associated with an immunochemical reaction between membrane-bound antigen and free antibody

AUTHOR(S): Aizawa, Masuo; Kato, Seishi; Suzuki, Shuichi  
CORPORATE SOURCE: Res. Lab. Resour. Util., Tokyo Inst. Technol., Tokyo, Japan

SOURCE: Journal of Membrane Science (1977), 2(2), 125-32  
CODEN: JMESDO; ISSN: 0376-7388

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A complex of cardiolipin antigen (cardiolipin, phosphatidylcholine, and

cholesterol) was immobilized in a triacetyl cellulose membrane. The membrane-bound antigen retained the immunochem. reactivity to bind specifically a corresponding free antibody (Wassermann antibody). A drastic membrane potential shift was assocd. with the immunochem. reaction between the membrane-bound antigen and the free antibody. The immunochem. induced potential shift is considered to result from a change of charge at the membrane-soln. interface. This immunoresponsive membrane could be used in a sensing system for sp. antibody protein detn.

CC 15-1 (Immunochemistry)

IT **Cardiolipins**

**Lecithins, uses and miscellaneous**

RL: BIOL (Biological study)

(immobilization in cellulose membrane of, Wassermann antibody detn. by)

IT **Antigens**

RL: BIOL (Biological study)

(membrane-bound, Wassermann antibody binding to membrane potential in relation to)

L93 ANSWER 45 OF 49 MEDLINE

DUPLICATE 5

ACCESSION NUMBER: 76032084 MEDLINE

DOCUMENT NUMBER: 76032084 PubMed ID: 1058468

TITLE: Antigen mobility in membranes and complement-medical immune attack.

AUTHOR: Humphries G M; McConnell H M

SOURCE: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1975 Jul) 72 (7) 2483-7.

Journal code: 7505876. ISSN: 0027-8424.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 197512

ENTRY DATE: Entered STN: 19900313

Last Updated on STN: 19970203

Entered Medline: 19751218

AB The complement fixing activity of liposomes containing cholesterol, dimyristoylphosphatidylcholine (or dipalmitoylphosphatidylcholine), and 3 mol % of cardiolipin has been studied as a function of cholesterol concentration by use of human syphilitic serum containing cardiolipin-specific (Wasserman) antibodies. It is found that complement fixation increases rapidly for cholesterol concentrations above 35 mol %. Spin label studies have been used to study the incorporation of cardiolipin in the relatively rigid phase of binary mixtures of cholesterol and dimyristoylphosphatidylcholine (or dipalmitoylphosphatidylcholine). It is concluded that cardiolipin is included in such a phase of these lipids for cholesterol concentrations above 35 mol %. These results indicate that a relatively rigid lateral distribution of this monovalent antigen in the plane of the membrane facilitates complement fixation and concomitant complement-mediated membrane damage.

CT Check Tags: Animal; Human; Support, U.S. Gov't, Non-P.H.S.

\***Antigens**

Binding Sites

**Cardiolipins: IM, immunology**

Cholesterol

Chromatography, Thin Layer

\*Complement

Complement Fixation Tests  
 Erythrocytes: IM, immunology  
 Kinetics

\*Membranes, Artificial  
 Models, Biological

**Phosphatidylcholines**

Rabbits: IM, immunology

Sheep: IM, immunology

Syphilis: IM, immunology

Temperature

RN 57-88-5 (Cholesterol); 9007-36-7 (Complement)

CN 0 (Antigens); 0 (Cardiolipins); 0 (Phosphatidylcholines)

L93 ANSWER 46 OF 49 WPIX (C) 2003 THOMSON DERWENT

ACCESSION NUMBER: 1975-02864W [02] WPIX

TITLE: Aq. antigen suspension for serodiagnosis of  
**syphilis** - using active carbon or carbon  
 activated by nitric acid as carrier.

DERWENT CLASS: B04 S03 S05

PATENT ASSIGNEE(S): (SUMO) SUMITOMO CHEM CO LTD

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 49046051	B	19741207	(197502)*		

PRIORITY APPLN. INFO: JP 1970-10530 19700205

AB JP 74046051 B UPAB: 19930831

The antigen and carrier of particle size 0.05-1.0  $\mu$  are suspended in water. The C is heated in 1-3N-nitric acid under reflux for about 2 hrs. in a water bath and washed repeatedly by decantation. After 3-5 days washing, Ph of the carrier dispersion becomes 4-5. The dispersion is neutralised with a sodium hydroxide soln. to pH 7.0. When active carbon is used in this case, the prod. cannot be used as such because it is irregular in size. So collection of the carbon with comparatively small particle size is repeated by decantation. The aq. suspension is obtd. by prep. a suspension of **cardiolipin**, **lecithin** and cholesterol by mixing 1 pt. of antigen contng. 0.03% **cardiolipin**, 0.9% cholesterol and 0.2% **lecithin** with 9 pts. of a buffered sodium chloride soln. contng. sodium chloride, disodium hydrogen phosphate and potassium dihydrogen phosphate is centrifuged at 3000 rpm. for about 15 mins. and the supernatant liq. is discarded. To the residual white ppte., is added the carbon dispersed in a buffer soln. at pH 6.0-7.0, and the resultant mixt. is well shaken to obtain a homogeneous suspension contng. **cardiolipin**, cholesterol, **lecithin** and carbon.

In order to increase **agglutination**, a metal chelating agent, e.g. EDTA or citric acid, an amine, e.g. ammonium chloride or ethanolamine, antiseptic, e.g. formalin, phenylmercuric nitrate or phenol and glycerol or ethylene glycol may be added to the carbon buffer soln. if needed. When one drop (1/60 ml.) of the prep. antigen suspension is mixed with 0.03-0.05 ml. of positive serum and allowed to react for 2-5 mins. with rotation, a visible black **agglutinated** mass appears.

L93 ANSWER 47 OF 49 MEDLINE

ACCESSION NUMBER: 74266946 MEDLINE  
 DOCUMENT NUMBER: 74266946 PubMed ID: 4366166  
 TITLE: A DNA antigen that reacts with antisera to cardiolipin.  
 AUTHOR: Guarneri M; Eisner D  
 SOURCE: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1974  
 May 20) 58 (2) 347-53.  
 Journal code: 0372516. ISSN: 0006-291X.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 197409  
 ENTRY DATE: Entered STN: 19900310  
 Last Updated on STN: 19900310  
 Entered Medline: 19740911

CT Check Tags: Animal; Male

- \*Antigens
- Binding Sites, Antibody
- \*Cardiolipins
- Cholesterol
- Chromatography, Thin Layer
- Coliphages
- Cross Reactions
- \*DNA
- DNA, Viral
- Escherichia coli
- Flocculation Tests
- Haptens
- Immune Sera
- Phosphatidylcholines
- Phosphatidylinositols
- RNA
- Rabbits: IM, immunology
- Saccharomyces cerevisiae
- Spermatozoa

RN 57-88-5 (Cholesterol); 63231-63-0 (RNA); 9007-49-2 (DNA)  
 CN 0 (Antigens); 0 (Binding Sites, Antibody); 0 (Cardiolipins); 0 (DNA,  
 Viral); 0 (Haptens); 0 (Immune Sera); 0 (Phosphatidylcholines); 0  
 (Phosphatidylinositols)

L93 ANSWER 48 OF 49 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1970:474975 HCPLUS  
 DOCUMENT NUMBER: 73:74975  
 TITLE: Synthetic substitutes for components of cardiolipin  
 antigen  
 AUTHOR(S): Reznikova, L. S.; Shvets, V. I.  
 CORPORATE SOURCE: Tsentr. Kozh.-Venerol. Inst., USSR  
 SOURCE: Vestnik Dermatologii i Venerologii (1970), 44(3),  
 58-62  
 CODEN: VDVEAV; ISSN: 0042-4609  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Russian  
 AB The antigenic properties of 9 substitutes of cardiolipin (i.e. .alpha.- and .beta.-glycerophosphatidic acids, L-.alpha.-(dimyristoyl) glyceryl phosphoric acid, bis-L-.alpha.-(dipalmitoyl)glyceryl phosphoric acid (I), .alpha.-phosphatidylglycerol, .alpha.-phosphatidylmyoinositol, oleic acid, stearic acid, .alpha.,.alpha.-diphosphatidylglycerol (II)) and 3

substitutes of lecithin (i.e. lysolecithin-lecithin, L-.alpha.-glycerylphosphorylcholine-lecithin, L-.alpha.-dioleoyllecithin (III)) were elucidated. The best results were obtained with I or II in combination with III. The testing of these antigens in the Wassermann test with 1720 different sera demonstrated almost complete coincidence (99.6%) of results with those obtained with normal cardiolipin antigen.

CC 13 (Immunochemistry)

IT **Antigens**

**Cardiolipins**

**Lecithins, biological studies**

RL: BIOL (Biological study)  
(substitutes for, in Wassermann reaction)

L93 ANSWER 49 OF 49 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1969:93335 HCPLUS

DOCUMENT NUMBER: 70:93335

TITLE: Lysozyme-cardiolipin-lecithin complexes

AUTHOR(S): Faure, Marguerite; Marechal, Jacqueline

CORPORATE SOURCE: Inst. Pasteur, Paris, Fr.

SOURCE: Bulletin de la Societe de Chimie Biologique (1968),  
50(9), 1537-46

CODEN: BSCIA3; ISSN: 0037-9042

DOCUMENT TYPE: Journal

LANGUAGE: French

AB Lysozyme on combination with cardiolipin gave stable water-insol. complexes. The dissocn. of the complexes by org. solvents was facilitated by lecithin. The lysozyme-cardiolipin (1:6) complex dissolved in heptane and in CHCl<sub>3</sub> on addn. of a large excess of cardiolipin, phospholipid, or lecithin. The complexes had no Wasserman antigen activity in vitro or in vivo. Lysozyme-cardiolipin-lecithin complexes were antigenic in the rabbit. They combined with the syphilitic reagin. They fixed complement with antibody, but were not agglutinated by it. This phenomenon was discussed.

CC 3 (Enzymes)

IT **Antigens**

RL: BIOL (Biological study)  
(cardiolipin-lecithin-lysozyme complexes)

IT **Lecithins, compounds**

RL: BIOL (Biological study)  
(cardiolipin-lysozyme complexes, antigenicity of)

IT **Cardiolipins**

RL: BIOL (Biological study)  
(lecithin-lysozyme complexes, antigenicity of)